Method for producing carotenoids from acid whey

By genetically modifying yeast cells, a biosynthesis pathway for producing carotenoids from acid whey is constructed, which solves the problems of pollution and unutilized value of acid whey, achieves efficient production of carotenoids, and improves the economic benefits of the dairy industry and Environmentally friendly effect.

CN118974260APending Publication Date: 2024-11-15MASSACHUSETTS INST OF TECH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029587.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-28
Filing Date
2023-01-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

As a by-product of the dairy industry, acid whey has caused environmental pollution without treatment, and its value has not been effectively utilized, making it difficult for the existing technology to be efficiently converted into high-value-added products.

Method used

By genetically modifying yeast cells, heterologous genes encoding enzymes with β-galactosidase, Leloir pathway and mevalonate pathway are introduced, and combined with protein engineering, to construct biosynthetic pathways for the production of carotenoids from acid whey, including tomatoes Synthesis of erythronin, β-carotene and astaxanthin.

Benefits of technology

The efficient production of carotenoid compounds from acid whey has been achieved, which solves the environmental pollution problem, while improving the economic benefits of the dairy industry and reducing waste treatment and transportation costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974260A_ABST
    Figure CN118974260A_ABST
Patent Text Reader

Abstract

Disclosed herein are metabolically engineered cells capable of producing carotenoids from acid whey.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Application No. 63 / 304,412, filed on January 28, 2022, entitled “Methods for producing carotenoids from acid whey,” the entire disclosure of which is incorporated herein by reference in its entirety.

[0003] References to Electronic Sequence Listings

[0004] The contents of the electronic Sequence Listing (M065670522WO00-SEQ-KVC.xml; size: 83,140 bytes; and creation date: January 19, 2023) are incorporated herein by reference in its entirety.

[0005] field

[0006] Provided herein are methods and compositions directed to the production of carotenoids from acid whey.

[0007] background

[0008] Acid whey (AW) is a liquid waste byproduct that, if untreated, poses a serious environmental problem due to its high organic content. In the United States, it is primarily produced during the preparation of the increasingly popular Greek yogurt, but there are other important sources around the world, such as the preparation of Indian cheese. It is estimated that more than 3 million tons of AW are generated in the United States each year. This presents an economic burden to the dairy industry, but it also presents a huge opportunity as it can be used to produce valuable products.

[0009] summary

[0010] The present disclosure relates at least in part to methods and compositions for producing carotenoids from acid whey. Aspects of the present disclosure relate to modified yeast cells capable of producing carotenoids from acid whey. In some embodiments, the present disclosure relates to modified yeast cells capable of converting acid whey into pyruvate by lactate metabolism, glucose metabolism, or galactose metabolism via the Leloir pathway. In some embodiments, the present disclosure relates to modified yeast cells capable of converting pyruvate into lycopene via the mevalonate pathway. In some embodiments, the present disclosure relates to modified yeast cells capable of converting lycopene into astaxanthin and / or lutein. In some embodiments, the modified yeast cells described herein are modified to overcome substrate inhibition. Aspects of the present disclosure relate to genetically modified yeast cells (modified cells) comprising: heterologous genes, wherein the heterologous genes encode enzymes having β-galactosidase (LacA) activity; one or more heterologous genes encoding one or more enzymes capable of converting lactate into pyruvate; one or more heterologous genes encoding one or more enzymes of the Leloir pathway; and one or more heterologous genes encoding one or more enzymes of the mevalonate pathway. In some embodiments, the modified cell is an oleaginous yeast cell.In some embodiments, the oleaginous cell is a Yarrowia lipolytica cell.

[0011] In some embodiments, one or more heterologous genes encoding one or more enzymes capable of converting lactate into pyruvate are selected from the group consisting of lactate transporter (JEN1) and lactate dehydrogenase (LDH). In some embodiments, one or more heterologous genes encoding one or more enzymes of the Leloir pathway are selected from the group consisting of GAL10M, GAL1, GAL7 and GAL10E. In some embodiments, one or more heterologous genes encoding one or more enzymes of the mevalonate pathway are selected from the group consisting of GGPPS, CarRP and CarB. In some embodiments, GGPPS is GGPPSxd derived from Xanthophyllomyces dendrorhous, GGPPSsa derived from Sulfolobusacidocaldarius, GGPPStc derived from Taxus canadensis, GGPPSpa derived from Pantoea agglomerans, and GGPPSyl derived from Yarrowia lipolytica.

[0012] In some embodiments, the modified cell further comprises a heterologous gene encoding an enzyme having lycopene β-cyclase activity. In some embodiments, the enzyme having lycopene β-cyclase activity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the enzyme having lycopene β-cyclase activity comprises an amino acid sequence shown in any one of SEQ ID NO: 2-4. In some embodiments, the modified cell further comprises heterologous genes encoding tHMGR, ERG12, IDI and ERG20 of the mevalonate (MVA) pathway, and / or choline kinase (CK) and isopentenyl phosphate kinase (IPK). In some embodiments, the modified cell further comprises: a heterologous gene encoding an enzyme having β-carotene ketolase (CrtW) activity; and a heterologous gene encoding an enzyme having β-carotene hydroxylase (CrtZ) activity. In some embodiments, an enzyme having CrtW activity is fused to an enzyme having CrtZ activity. In some embodiments, the CrtW / CrtZ fusion enzyme comprises a localization signal. In some embodiments, the localization signal targets the CrtW / CrtZ fusion enzyme to the endoplasmic reticulum, peroxisome, and / or lipid body.

[0013] In some embodiments, the modified cell further comprises a heterologous gene encoding an enzyme having lycopene β cyclase activity and / or a heterologous gene encoding an enzyme having lycopene ε cyclase activity. In some embodiments, the enzyme having lycopene β cyclase activity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the modified cell further comprises a heterologous gene encoding an enzyme having carotenoid hydroxylase 1 (LUT1) activity and / or a heterologous gene encoding an enzyme having carotenoid hydroxylase 5 (LUT5) activity.

[0014] In some embodiments, the modified yeast cells described herein are capable of overcoming substrate inhibition. As used herein, the term "substrate inhibition" refers to the most common deviation from Michaelis-Menten kinetics, occurring in approximately 25% of known enzymes. Substrate inhibition occurs when the concentration of an enzyme substrate exceeds optimal parameters and reduces the growth rate of the cell.

[0015] Another aspect of the present disclosure relates to a genetically modified yeast cell (modified cell) comprising: a first heterologous gene, wherein the first heterologous gene encodes an enzyme having β-carotene ketolase (CrtW) activity; and a second heterologous gene, wherein the second heterologous gene encodes an enzyme having β-carotene hydroxylase (CrtZ) activity; wherein the modified cell produces β-carotene. In some embodiments, the modified cell is an oleaginous yeast cell. In some embodiments, the oleaginous cell is a Yarrowia lipolytica cell. In some embodiments, the enzyme having CrtW activity is fused to an enzyme having CrtZ activity. In some embodiments, the CrtW / CrtZ fusion enzyme comprises a localization signal. In some embodiments, the localization signal targets the CrtW / CrtZ fusion enzyme to the endoplasmic reticulum, peroxisomes and / or lipid bodies.

[0016] Another aspect of the present disclosure relates to a method for converting a carbon source into lycopene and / or beta-carotene, the method comprising: contacting a modified cell as described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into lycopene and / or beta-carotene. In some embodiments, the carbon source is acid whey. In some embodiments, the carbon source is converted into lycopene. In some embodiments, the carbon source is converted into beta-carotene.

[0017] Another aspect of the present disclosure relates to a method of converting a carbon source into astaxanthin, the method comprising: contacting a modified cell described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into astaxanthin. In some embodiments, the carbon source is acid whey.

[0018] Another aspect of the present disclosure relates to a method of converting a carbon source into alpha-carotene, the method comprising: contacting a modified cell described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into alpha-carotene. In some embodiments, the carbon source is acid whey.

[0019] Another aspect of the present disclosure relates to a method of converting a carbon source into lutein, the method comprising: contacting a modified cell described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into lutein. In some embodiments, the carbon source is acid whey.

[0020] Another aspect of the present disclosure relates to an enzyme having lycopene β cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 2. Another aspect of the present disclosure relates to an enzyme having lycopene β cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 3. Another aspect of the present disclosure relates to an enzyme having lycopene β cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 4.

[0021] Each limitation of the present invention may encompass various embodiments of the present invention. Therefore, it is contemplated that each limitation of the present invention involving any element or combination of elements may be included in each aspect of the present invention. The present invention does not limit its application to the construction details and component settings set forth in the following description or illustrated in the accompanying drawings. The present invention can have other embodiments and can be practiced or implemented in various ways. In addition, the wording and terminology used in this disclosure are for descriptive purposes and should not be considered restrictive. "Including / comprising / containing (including)", "comprising / containing (comprising)" or "having", "including / containing / containing (containing)", "involving" and its variants used in this disclosure are intended to cover the items listed thereafter and their equivalents and other items. As used in this specification and the appended claims, the singular forms "one / an / a (a)", "one / an / a (an)" and "the / said (the)" include plural indicators unless the content clearly stipulates otherwise.

[0022] The details of one or more embodiments of the invention are set forth in the following description. Other features or advantages of the invention will be apparent from the following drawings and detailed description of several embodiments, as well as from the appended claims.

[0023] BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The following drawings constitute part of this specification and are included to further illustrate certain aspects of the present disclosure, which may be better understood by reference to one or more of these drawings in conjunction with the detailed description of specific embodiments presented in the present disclosure. The drawings are not drawn to scale. The drawings are for illustration purposes only and are not required for practicing the present disclosure. For clarity, not every component is labeled in every drawing. In the drawings:

[0025] Figures 1A-1C . Figure 1A , consumption of sugars and organic acids present in AW by engineering Y. lipolytica strains (Lac, lactose; Glu, glucose; Gal, galactose). Figure 1B , cellular biomass and lipid production during fermentation. Figure 1C , fatty acid composition of yeast cells.

[0026] Figure 2 .Metabolic pathway for the synthesis of carotenoids from lycopene.

[0027] Figure 3Overview of the metabolic engineering efforts required for the biosynthesis of lycopene from AW using Yarrowia lipolytica. Lactose hydrolysis involved the introduction of β-galactosidase (LacA), enhanced lactate conversion to pyruvate involved overexpression of lactate transporter (JEN1) and dehydrogenase (LDH), accelerated native galactose metabolism was achieved by overexpression of Leloir pathway genes, and lycopene biosynthesis involved the introduction of three heterologous genes: geranylgeranyl diphosphate synthase (GGPPxd), phytoene synthase (CarRP), and phytoene desaturase (CarB).

[0028] Figure 4 .Engineering subcellular astaxanthin biosynthetic pathway in Yarrowia lipolytica. Cytosolic acetyl-CoA is a common precursor for lipid formation and astaxanthin synthesis. β-Carotene synthesized in the endoplasmic reticulum (ER) is sequestered into lipid bodies (LB) aggregated by triacylglycerols (TAG). The stored TAG is hydrolyzed into free fatty acids (FFA), transported to peroxisomes with β-carotene translocation, and converted to acetyl-CoA by β-oxidation. The genes involved in the previously engineered β-carotene biosynthetic pathway in Yarrowia lipolytica are GGPPsa, CarRP, and CarB. CrtW / Z (CrtW and CrtZ) are the heterologous subcellular engineered enzymes associated with astaxanthin biosynthesis in this study. GGPPsa, geranylgeranyl diphosphate synthase from Sulfolobus acidocaldarius; CarRP, bifunctional phytoene synthase / lycopene β-cyclase from Mucor circinelloides; CarB, phytoene dehydrogenase from M. circinelloides. CrtW, β-carotene ketolase; CrtZ, β-carotene hydroxylase. IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate; FPP, farnesyl diphosphate; GGPP, geranylgeranyl diphosphate; FBP, fructose 1,6-bisphosphatase; DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde 3-phosphate; PA, phosphatidic acid; DAG, diacylglycerol. Dashed arrows indicate multiple catalytic steps.

[0029] Figure 5A-5B .Optimization of astaxanthin production. Figure 5A , the astaxanthin biosynthesis pathway starting from β-carotene was constructed by introducing β-carotene ketolase (CrtW) and hydroxylase (CrtZ). Pathway expression was accompanied by a colony color change from yellow to red. Figure 5B, by testing CrtW and CrtZ from different organisms to maximize astaxanthin production. The best combination of PsCrtW from Paracoccus sp. and HpCrtZ from Haematococcus pluvialis produced the highest astaxanthin production after 72 hours of shake flask culture. Different construct combinations are marked below each bar (black circles indicate inclusion; blanks indicate exclusion). The mean and standard deviation (sd) of three independent experiments are shown.

[0030] Figures 6A-6C .Astaxanthin biosynthesis of different fusion constructs in Yarrowia lipolytica. Fig. 6A , astaxanthin biosynthetic pathway. Depending on the order of ketolysis and hydroxylation conferred by CrtW and CrtZ, respectively, multiple pathways from β-carotene to astaxanthin may exist, which lead to the formation of different intermediates (indicated by numbers). CrtW, β-carotene ketolyase; CrtZ, β-carotene hydroxylase. Figure 6B , HPLC traces of carotenoids from flask cultures of astaxanthin-producing strains expressing either fusion CrtW-Z or individual enzymes CrtW+Z. Compared to the YL02 strain containing individual enzymes CrtW+Z, the accumulation of canthaxanthin (④) and zeaxanthin (⑥) was significantly reduced in the fusion CrtW-Z strain, while the intermediate 3'-hydroxyechinone (⑤) accumulated to a higher level. Figure 6C , astaxanthin accumulation in strains containing functional fusion enzymes. Astaxanthin levels were significantly increased in strains expressing the fusion enzymes compared to control strains expressing the individual enzymes CrtW+Z. The CrtW-Z fusion strain showed further enhanced performance over the CrtZ-W fusion type. Linker sequence, GGGGSGGPGS (SEQ ID NO: 5). Means and sd of three independent experiments are shown.

[0031] Figures 7A-7D .Subcellular organelle engineering further promotes astaxanthin biosynthesis. Fig. 7A , Schematic representation of astaxanthin biosynthesis when the fusion enzyme CrtW-Z-dependent pathway is targeted to the endoplasmic reticulum (ER), lipid bodies (LB), and peroxisomes by fusing to KDEL, oleosin, and SKL sequences, respectively. Figure 7B , Chromatographic carotenoid profiles of organelle-targeted strains. The accumulation of intermediates, especially 3'-hydroxyechinone (⑤), echinone (②), and β-carotene (①), was significantly reduced in strains with two (ER and LB) or three (ER, LB, and peroxisome) organelles engineered compared to strains with cytoplasmic expression. Figure 7C-7D, assembling the astaxanthin pathway to subcellular organelles further accelerated the conversion of β-carotene to astaxanthin. In addition, the fusion enzyme CrtW-Z was simultaneously targeted to all three organelles LB, ER and peroxisome, producing the highest astaxanthin titer after 72 hours of shaking flask culture in YPD medium. Different construct combinations are marked below each bar (+, with organelle targeting; -, without organelle targeting). The mean and sd of three independent experiments are shown. Statistical differences were analyzed using the Student's t-test, and P<0.05 was considered statistically significant. ***P<0.001; **P<0.01.

[0032] Figures 8A-8C . Strains engineered for astaxanthin production achieved high titers in fed-batch cultures. Fig. 8A , astaxanthin production by strain YL17 cultured in YPD medium containing different initial glucose concentrations (20, 30, 40, and 50 g / L). Figures 8B-8C , in a conical flask ( Figure 8B ) and 3-L bioreactor ( Figure 8C ) Fed-batch fermentation profile of astaxanthin-producing strain YL17. Means and sd of three independent experiments are shown.

[0033] Fig. 9 HPLC analysis of carotenoids in strains containing the fusion enzymes CrtZ-W or CrtW-Z. ①, β-carotene; ②, echinone; ④, canthaxanthin; ⑤, 3'-hydroxyechinone; ⑥, zeaxanthin; ⑨, astaxanthin.

[0034] Figures 10A-10B . Fig. 10A , Effect of an additional copy of the fusion enzyme CrtW-Z on astaxanthin production in the engineered strain. Each plus sign (+) indicates that one copy of the gene was integrated into the genome. Means and sd of three independent experiments are shown. Fig. 10B , HPLC analysis of carotenoids in the engineered strain YL12 containing an additional copy of the fusion enzyme CrtW-Z. ①, β-carotene; ②, echinone; ④, canthaxanthin; ⑤, 3'-hydroxyechinone; ⑥, zeaxanthin; ⑨, astaxanthin.

[0035] Fig.11 Microscope image of a cell producing beta-carotene. Large amounts of beta-carotene are clearly accumulated in the lipid bodies of the cell.

[0036] Figures 12A-12C . The β-carotene biosynthetic enzyme GGPPsa was predicted using TMHMM server v.2.0 ( Fig. 12A )、CarRP( Fig. 12B ) and CarB( Fig. 12C) in the transmembrane helices.

[0037] Fig.13 .Subcellular localization of β-carotene biosynthetic enzymes GGPPsa, CarRP, and CarB by fusion with GFP protein, respectively.

[0038] Fig.14 .Carotenoid chromatograms of engineered strain YL17 cultured in different media. The only difference between the media was the initial glucose concentration. YPD20, 20 g / L glucose; YPD30, 30 g / L glucose; YPD40, 40 g / L glucose; YPD50, 50 g / L glucose. ①, β-carotene; ②, echinone; ④, canthaxanthin; ⑤, 3'-hydroxyechinone; ⑥, zeaxanthin; ⑨, astaxanthin.

[0039] Fig.15 . Dry cell weight (DCW) and OD of astaxanthin-producing cells 600 According to the measured OD 600 And apply the conversion factor to calculate DCW.

[0040] Figures 16A-16D .Lycopene cyclase exhibits substrate inhibition effect. Fig.16A , lycopene inhibits its downstream enzyme lycopene cyclase through substrate inhibition. Therefore, a higher rate of lycopene formation than its subsequent conversion to β-carotene exacerbates this imbalance, leading to the accumulation of lycopene. Fig. 16B , after 3 days of fermentation in YPD medium, the β-carotene levels in strains expressing relevant biosynthetic genes from different sources indicated that the CarB / CarRP pair reached a higher performance level. Fig. 16C , Heterologous overexpression of GGPP synthase from X. dendrorhous (GGPPxd) increased the production of β-carotene but also resulted in a significant accumulation of its biosynthetic precursor lycopene. ND, not detected. Fig.16D , measurement of relative lycopene cyclase catalytic activity showed that the activity of wild-type CarRP (or CarR) was biphasic with respect to lycopene concentration, indicating substrate inhibition. In contrast, CarRP (or CarR) variant Y27R showed no substrate inhibition at all. CarR, truncated CarRP without P domain. Figures 16B-16D , Means and standard deviations (sd) of three independent experiments are shown.

[0041] Figures 17A-17E .Eliminating substrate inhibition through protein engineering. Fig.17A, using the predicted protein model, several positions within the R domain of CarRP (lycopene cyclase) were identified as suitable locations for mutation to reduce substrate inhibition. Single substitutions are represented by light spheres, while double substitutions are represented by dark spheres. Fig. 17B , a total of 50 generated variants were tested for β-carotene selectivity. Y27R, V175W, and T31R-F92W (boxed) showed significantly increased β-carotene selectivity compared to wild type (WT), indicating reduced substrate inhibition. Data represent the average of two independent experiments. Figures 17C-17D Compared with the control strain YLMA03 containing wild-type CarRP, these variants showed significantly increased β-carotene production and decreased lycopene accumulation ( Fig. 17C In particular, the strain YLMA11 expressing CarRP(Y27R) showed a high selectivity of 98% ( Fig.17D ) and achieved a titer of 2.38 g / L ( Fig. 17C ). Fig.17E Elimination of substrate inhibition allowed higher flux through the carotenoid synthesis pathway (via MVA and IUP overexpression), increasing β-carotene titer while maintaining high selectivity. Ultimately, 4.22 g / L β-carotene was produced in YLMA15 with a selectivity of ~98%. For cultures using strains containing IUP, 30 mM prenyl alcohol ( Fig.31 ).for Fig. 17C and 17E , Means and s.d. of three independent experiments are shown.

[0042] Figures 18A-18G .GGPPS-mediated metabolic flux limiter effectively alleviates substrate inhibition. Fig.18A , the GGPPS-mediated metabolic flux limiter alters the amount of flux through the carotenoid synthesis pathway, thereby regulating the rate of lycopene formation. Fig.18B By expressing enzymes from different organisms in Yarrowia lipolytica, altered GGPPS activity can be achieved, as indicated by changes in the rate of GGPP synthesis in vivo. For these experiments, a po1f background strain with no modifications other than GGPPS expression was used. Fig.18C , compared with the strain expressing GGPPxd, the other strains containing less active GGPPS relieved substrate inhibition of lycopene cyclase. The slower formation rate of lycopene prevented its accumulation, and thus almost all lycopene was converted to β-carotene. ND, not detected. Fig.18DThe fermentation time course showed that the balanced pathway with attenuated GGPPsa (YLMA25) resulted in the least accumulation of lycopene throughout the experiment, which is consistent with YLMA11 containing the Y27R variant of CarRP. In contrast, rapid accumulation of lycopene was observed in the strain with extremely potent GGPPxd (YLMA03). Fig.18E , the gene expression cassettes containing the balanced pathway (GGPPsa, CarB and CarRP) were sequentially introduced into the po1f-T strain for β-carotene production. With higher copy numbers, the β-carotene titer increased to 2.13 g / L, and the selectivity of β-carotene was maximized. Fig.18F , overexpression of MVA and IUP further improved β-carotene synthesis while maintaining its high selectivity. Figure 18G , using the extremely potent GGPPxd to intentionally trigger substrate inhibition, together with a mutant CarRP(E78K), a lycopene-producing strain was constructed that achieved a titer of 2.62 g / L. ND, not detected. Figures 18B-18G , Means and s.d. of three independent experiments are shown.

[0043] Figures 19A-19D Balancing the distribution of acetyl-CoA between lipid and isoprenoid synthesis favors carotenoid accumulation. Fig.19A , cytosolic acetyl-CoA is shared by two competing pathways, de novo lipid biosynthesis and the MVA pathway. However, lipid bodies within the cell form hydrophobic zones in which carotenoids can be sequestered, thus promoting their accumulation. Therefore, both pathways are required, and optimal flux allocation is critical to achieve high carotenoid titers and per-cell content. In addition, intracellular TAG can be used as a carbon source for acetyl-CoA production, which in turn provides the building blocks for carotenoids. Fig.19B , the lipid content depends on the C / N ratio of the culture medium, and a higher C / N ratio promotes lipid production. Figures 19C-19D , β-carotene titer ( Fig.19C ) and content ( Fig.19D ) is also a function of the C / N ratio of the culture medium. However, unlike lipid content, which increases monotonically with the C / N ratio, there is an optimum for β-carotene production. 10 P 10 D 50 In the culture medium, the highest titer and content of β-carotene per cell occurred at a C / N ratio of 9:1. Figures 19B-19D , Means and s.d. of three independent experiments are shown.

[0044] Figures 20A-20C During the stationary phase following glucose depletion, cellular lipids drive carotenoid biosynthesis via β-oxidation. Fig. 20AMonitoring glucose concentration, lipid content, and β-carotene content throughout the fermentation revealed that β-carotene continued to increase after glucose was depleted from the medium. At the same time, intracellular lipids dropped rapidly after glucose depletion, suggesting that cells were mobilizing TAG as an alternative carbon source when glucose was no longer available. Figures 20B-20C , tracking from [U- 13 C] carbon from cells grown in glucose and naturally abundant stearic acid, indicating that β-oxidation may be the source of acetyl-CoA destined for carotenoid synthesis. Means and standard deviations of three independent experiments are shown.

[0045] Figures 21A-21F . Bioreactor fermentation of engineered strains for β-carotene and lycopene. Fig.21A and 21D , β-carotene-producing strain YLMA15 ( Fig.21A ) and lycopene-producing strain YLMA34 ( Fig.21D ) Fermentation profile in a 3-L bioreactor. Fig.21B and 21E , β-carotene cultures showed a deep red-orange color after 240 hours of cultivation ( Fig.21B ), while the lycopene culture showed a deep red color ( Fig.21E ). Fig. 21C and 21F , producing β-carotene ( Fig. 21C ) and lycopene ( Fig.21F ) cells. β-Carotene and lycopene accumulated intracellularly and dispersed throughout the cytoplasm in most cells. Fig.21A and Fig.21D , Means and s.d. of three independent experiments are shown.

[0046] Fig. 22. Diagram of metabolic pathways leading to β-carotene production in Yarrowia lipolytica. The engineered β-carotene biosynthetic pathway involves directly upregulated genes from the mevalonate pathway (black), the isopentenol utilization pathway (IUP) (white), and β-carotene synthesis (dashed line). HMG-CoA, hydroxymethylglutaryl-CoA; MVA, mevalonate; MVAP, mevalonate-5-phosphate; IP, isopentenyl monophosphate; IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate; GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate. tHMGR, truncated HMG-CoA reductase; ERG12, mevalonate kinase; IDI, isopentenyl diphosphate isomerase; ERG20, geranyl / farnesyl diphosphate synthase; GGPPS, GGPP synthase. CrtYB or CarRP, bifunctional phytoene synthase / lycopene β-cyclase; CrtI or CarB, phytoene dehydrogenase. CK, choline kinase; IPK, isopentenyl phosphate kinase.

[0047] Fig.23 Disruption of TRP1 in the Yarrowia lipolytica po1f strain via Crispr-Cas9. A single adenine deletion (single underline at position -110) resulted in a frameshift mutation (double underline) that abolished TRP1 activity.

[0048] Figures 24A-24D .Effects of engineering the lycopene β-cyclase step on β-carotene production. Fig.24A CarRP is a bifunctional enzyme in which the R and P domains confer lycopene cyclase and phytoene synthase activities, respectively. Two approaches were used to isolate the cyclase activity: truncating the CarRP gene after the R domain and generating a loss-of-function mutation (D409G) in the P domain. Fig. 24B , increasing the copy number of lycopene β-cyclase did not improve β-carotene synthesis. Fig.24C , relative gene expression levels correlated with increased CarRP copy numbers. Fig.24D , expressing lycopene β-cyclase from various other organisms resulted in improved β-carotene titers. However, the gain was small and lycopene accumulation was still observed. Means and standard deviations (sd) of three independent experiments are shown.

[0049] Fig.25 Levels of intermediates involved in the β-carotene synthesis pathway. The intracellular concentrations of biosynthetic intermediates from FPP to β-carotene were measured, as well as lycopene as the only aggregate precursor. The data shown are the means and s.d. of three independent experiments.

[0050] Fig.26 .Structure prediction of lycopene β-cyclase in CarRP. Schematic diagram of the CarRP protein showing six transmembrane helices located within the R domain (β-cyclase).

[0051] Fig. 27 Computational model of the R domain of CarRP (lycopene cyclase). The model has a TrRosetta confidence score of 0.79, which indicates high certainty in the structural model.

[0052] Fig.28 Variants were clustered to illustrate distances between sequences. Variants were clustered using PhyML to ensure the spread of the tested variants.

[0053] Fig.29 .Relative gene expression levels are associated with CarRP variants. The relative expression levels of gene CarRP in engineered strains containing mutant CarRP and wild-type CarRP (WT) were quantified by RT-PCR. ACT1 was used as an internal control gene for normalization. Data shown are the mean and sd of three independent experiments.

[0054] Fig.30 . Spatial mapping of substitutions that remove substrate inhibition. The positions of successful variants were mapped onto a computational model of lycopene cyclase, with Y27R, V175W and T31R-F92W shown as spheres. All substitutions appear to be located in the same spatial region of the enzyme.

[0055] Fig.31 Effect of isoprenol or prenol on cell growth. The isoprenol isomers, isoprenol or prenol, were supplied to the po1f strain in YPD medium at different concentrations. OD was measured after 24 h of culture. 600 Based on these results, 30 mM isoprenol or 10 mM isoprenol was found to be a suitable concentration for all subsequent experiments. The data shown are the means and s.d. of three independent experiments.

[0056] Figures 32A-32B .Disruption of lycopene cyclase activity in CarRP. Fig.32A , the E78K mutation in the R domain of CarRP (as indicated by the dashed rectangle) results in loss-of-function cyclase activity. Fig.32B , HPLC chromatogram showing mutant CarRP E78K Beta-carotene formation is completely eliminated.

[0057] Fig.33Engineering the MVA pathway and IUP further promoted lycopene biosynthesis. Overexpression of native genes in the MVA pathway improved lycopene synthesis. Moreover, additional introduction of IUP in the lycopene-producing strain further improved the titer. Data shown are the mean and s.d. of three independent experiments.

[0058] Fig.34 Composition of modified YPD and YNB media used in this study.

[0059] Fig.35 .Determination of the optimal initial glucose concentration for β-carotene production in Y5P cells 10 D n After 3 days of fermentation, the amount of glucose consumed, OD 600 and β-carotene titer. The optimal initial glucose concentration was found to be 50 g / L. Above this concentration, the performance of the strain was adversely affected and the glucose consumption rate was also reduced, which may be due to osmotic stress. The mean and sd of three independent experiments are shown. Statistical differences were analyzed using Student's t-test, and P < 0.05 was considered statistically significant. *P < 0.05.

[0060] Fig.36 Comparison of cell growth in media with different C / N ratios. In these experiments, the YLMA15 strain was used and it was found that the biomass decreased with increasing C / N ratio. The data shown are the mean and s.d. of three independent experiments.

[0061] Fig.37 .Use optimized Y 10 P 10 D 50 The data shown are the mean and SD of three independent experiments.

[0062] Fig.38 Microscopic morphology of YLMA15 cells throughout the fermentation. Cells collected at different time points throughout the culture were observed under a microscope and the observations were consistent with the fermentation profile. In the presence of glucose in the medium during the initial 3 days, lipid droplets within the cells gradually aggregated into liposomes, which sequestered the produced β-carotene. However, liposomes were no longer visible during the later stages of glucose depletion due to TAG decomposition, which in turn caused the accumulated β-carotene to be more dispersed throughout the cells.

[0063] Fig.39 HPLC chromatogram of carotenoids obtained from YLMA15 after fed-batch fermentation. The selectivity for β-carotene was calculated based on the relative contents of lycopene and β-carotene.

[0064] Figures 40A-40B .β-carotene producing cells ( Fig.40A ) and lycopene-producing cells ( Fig.40B ) and OD 600 According to the measured OD 600 And apply the conversion factor to calculate DCW.

[0065] Details

[0066] The present disclosure relates to methods for converting industrial waste (e.g., dairy waste) into valuable food and feed ingredients (e.g., carotenoids) and / or microbial animal feed using engineered yeast cells. These ingredients can be naturally occurring products that belong to the isoprenoid (also known as terpenoid) family and are primarily synthesized by plants. Specifically, the present disclosure describes the synthesis of carotenoid compounds such as lycopene, beta-carotene, and astaxanthin from dairy industrial waste, as well as metabolic and protein engineering strategies for enhancing their synthesis. Other products of the isoprenoid family can also be similarly synthesized from acid whey (AW) waste.

[0067] Currently, the two most common uses of AW are to add it directly to the soil as a fertilizer, or to mix it with silage and feed it to livestock. However, in both cases, the amount of AW that can be used is limited, and these are low-value applications. In contrast, processing AW in wastewater treatment facilities increases the production costs of many food products. Overall, there is no good solution when a large amount of potential fermentable nutrients (such as lactose, galactose, and lactic acid) remains unutilized (Menchik et al., 2019). In addition, this pale yellow AW byproduct is not attractive to the food industry because its sour and salty taste, high levels of ash, and low levels of protein limit its food applications (Lievore et al., 2015).

[0068] Dairy industry companies have been trying to develop alternative methods for processing AW. For example, Chobani (Norwich, New York) and Commonwealth Dairy (Brattleboro, Vermont) use reverse osmosis filtration systems to recover water from AW and reduce transportation costs. Other companies, such as General Mills (Minneapolis, Minnesota), use anaerobic digestion to convert AW into methane, which can then supply generators via methane to meet part of the factory's energy needs. However, these are low value-added processes, and the income generated by converting AW into methane is relatively low. General Mills has also developed a method for neutralizing AW to use it in food products as a filler or nutritional fortifier (U.S. Patent Publication 2014 / 0348981), or to produce oligosaccharides that can be used as soluble fibers in cereals or baked goods (U.S. Patent Publication 2014 / 0348979). Danone describes a method for generating AW with a stable lactose content so that the method of separating lactose can be more consistent (International Patent No. WO 2016 / 177701A1). Arla Food Ingredients (Viby, Denmark) and Ultima Foods (Quebec, Canada) are attempting to minimize AW generation during food production using protein solutions and ultrafiltration, respectively.

[0069] In addition to dairy companies, many research groups have tried to find ways to utilize AW. For example, a method for producing glucose / galactose syrup and whey protein from AW has been proposed, which uses a combination of ultrafiltration and acid-catalyzed thermal hydrolysis of lactose (Lindsay et al., 2018). However, this method requires expensive ultrafiltration membranes to separate whey protein and high temperatures to hydrolyze lactose. In addition, undesirable acid-catalyzed degradation reactions limit product yields, and the value of the final product is low. Medium-chain carboxylic acids (MCCA), such as n-hexanoic acid, have been another group of compounds that have been used as products of AW fermentation using microbiota (Xu et al., 2018). The use of a single bioreactor results in low specificity regarding MCCA production; therefore, more complex systems must be used to stage the microbiota into different operating conditions. This system using serial bioreactors increases process costs and faces challenges in scalability. Recently, AW has been used as an alternative growth medium for microalgae aimed at producing the enzyme β-galactosidase (Bentahar et al., 2019). In another work, the researchers attempted to convert lactose present in AW into galacto-oligosaccharides (GOS) using two commercially available β-galactosidases from Aspergillus niger and Kluyveromyces lactis, achieving low GOS yields.

[0070] In addition, there are several reports mentioning the use of AW in fermented milk beverages to take advantage of the nutrients found in AW and replace water (Lievore et al., 2015; Skryplonek et al., 2019). However, the salty and sour taste of AW detracts from the essential characteristics of fermented beverages in terms of flavor, aroma, and aftertaste. In addition, it has been reported that the use of AW in fermented milk products changes the viscosity of the product and, therefore, the texture of the product, leading to lower preference during sensory evaluation (Lievore et al., 2015). Masking the flavor and smell of AW would require the addition of additional ingredients, albeit at an increased cost.

[0071] Natural products are a rich source of bioactive molecules whose diverse properties support a wide range of applications in the pharmaceutical, food, and flavor and fragrance industries (Atanasov et al., 2015; Cragg, 1998; Dhingra et al., 1999; Dzubak et al., 2006; Zhou et al., 2009). Due to their structural complexity and extremely low content in natural sources, the chemical synthesis and extraction of these compounds from plants face special challenges (Chemler and Koffas, 2008; Martin et al., 2003), prompting efforts to produce them through engineered microorganisms. Most metabolic engineering efforts for the production of chemical products have focused on manipulating the functional reconstruction of metabolic pathways in the cytosol. However, due to the complexity of cellular metabolism, involving a large number of crosstalks and complex regulatory mechanisms, this strategy often results in poor yields or the formation of undesirable byproducts (Ajikumar et al., 2010; Martin et al., 2003). In this regard, the natural intracellular compartmentalization of eukaryotic cells may provide inspiration for the types of metabolic engineering that successfully address these challenges (Hammer and Avalos, 2017).

[0072] The present disclosure also relates to the construction of engineered yeast cells by applying metabolic and protein engineering strategies, thereby allowing the use of glucose or AW as raw materials to produce intracellular carotenoid compounds at high concentrations. After the purification step, the carotenoid compounds can be used as antioxidants (food fortification), food colorants, dietary supplements, feed additives, and in cosmetics or personal care products. Another product can be a microbial animal feed rich in carotenoids.

[0073] The main advantages of this technology are: (1) no pretreatment of AW is required and the bioprocess can be carried out under non-sterile conditions, (2) full utilization of AW, generating a water stream free of organic compounds, (3) synthesis of high value-added specialty ingredients and co-production of microbial animal feed, which is beneficial to process economics, (4) the ability to use dilute and concentrated AW, (5) the fermentation process is simple and scalable, (6) GRAS host microorganisms allow the technology to be safely applied to existing creamery facilities, which also means immediate access to raw materials, (7) the floor space occupied is comparable to that occupied by AW storage tanks, and (8) a significant increase in revenue compared to food product generation and a reduction in costs associated with waste disposal and transportation of AW to farms, leading to, for example, a 38% increase in revenue compared to current Greek yogurt manufacturing.

[0074] The present disclosure also relates to methods for distinguishing metabolic pathways within yeast subcellular organelles. Subcellular organelles have received increasing attention due to their unique physicochemical environments and enzyme, metabolite and cofactor content (which can provide favorable conditions for the operation of different metabolic pathways) (Ayer et al., 2013; Hammer and Avalos, 2017). Assembling pathways within smaller subcellular compartments not only increases local substrate and enzyme concentrations, thereby leading to faster reaction rates, but also prevents intermediates from being diverted to competing pathways (Avalos et al., 2013). To date, most explorations of metabolic pathway compartmentalization in yeast have been conducted on the model organism Saccharomyces cerevisiae, including the use of mitochondria to produce fuels, chemicals, and drugs (Avalos et al., 2013; Farhi et al., 2011; Szczebara et al., 2003; Yuan and Ching, 2016), compartmentalized pathways in peroxisomes (Sheng et al., 2016; Zhou et al., 2016), targeting the endoplasmic reticulum and Golgi apparatus to produce fuels and drugs (Thodey et al., 2014), and vacuolar compartmentalization (Bayer et al., 2009). Targeting biosynthetic pathways to these subcellular compartments is beneficial for the production of desired products in this organism. On the other hand, despite these advantages of organelle engineering, its full potential in the oleaginous yeast Yarrowia lipolytica remains largely unexplored. Due to the unique ability of this yeast to accumulate large amounts of intracellular lipids in the form of lipid droplets, there is an opportunity to exploit the promise of pathway compartmentalization in this yeast.

[0075] Astaxanthin is a high-value carotenoid-derived pigment that has attracted increasing attention due to its wide applications in food, animal feed, nutraceuticals, cosmetics, and pharmaceutical industries (Ambati et al., 2014). These applications are attributed to its potent antioxidant effects (Hama et al., 2012), anti-inflammatory effects (Bennedsen et al., 2000), and anticancer activities (Chew et al., 1999). Traditional methods for the production of astaxanthin include chemical synthesis and extraction from natural sources. However, biosafety issues of chemical routes and the high cost and variability of products produced by extraction routes limit its widespread application (Qi et al., 2020). Additionally, metabolic pathway engineering for astaxanthin biosynthesis has been successfully demonstrated in various host organisms, typically occurring in the cytoplasm (Diao et al., 2020; Gong et al., 2020; Henke et al., 2018; Jiang et al., 2020; Jin et al., 2018; Kildegaard et al., 2017; Lemuth et al., 2011; Li et al., 2020; Lu et al., 2017; Ma et al., 2016; Nogueira et al., 2019; Park et al., 2018; Qi et al., 2020; Scaife et al., 2009; Scaife et al., 2012; Tramontin et al., 2019; Ukibe et al., 2009; Wang et al., 2017; Zhang et al., 2018; Zhou et al., 2019; Zhou et al., 2017; Zhou et al., 2015). Astaxanthin production in these engineered microorganisms is quite low for cost-effective commercialization, mainly due to the poor conversion efficiency of the precursor β-carotene to astaxanthin.

[0076] Metabolic engineering methods for producing high-value chemicals in microorganisms mostly use the cytosol as a general reaction vessel. However, the isolation of enzymes and substrates and metabolic crosstalk often prevent the effective synthesis of target compounds in the cytosol. Organelle compartmentalization in eukaryotic cells suggests a way to overcome these challenges. In some embodiments, the present disclosure relates to expressing the astaxanthin biosynthetic pathway in subcellular organelles of the oleaginous yeast Yarrowia lipolytica. In some embodiments, the enzymes of the astaxanthin pathway can be fused together to improve substrate activity and reaction efficiency. In some embodiments, the fusion of two enzymes (β-carotene ketolase and hydroxylase) that convert β-carotene to astaxanthin performs better than the expression of a single enzyme. In some embodiments, a single or fused enzyme of the astaxanthin biosynthetic pathway is expressed in a compartment of a liposome, endoplasmic reticulum or peroxisome. In some embodiments, targeting the astaxanthin pathway to a subcellular organelle not only accelerates the conversion of β-carotene to astaxanthin, but also significantly reduces the accumulation of ketocarotenoid intermediates.

[0077] The present disclosure relates at least in part to methods and compositions for producing carotenoids from acid whey. Aspects of the present disclosure relate to modified yeast cells (e.g., oleaginous yeast cells) capable of producing carotenoids from acid whey. As used herein, the term "oleaginous yeast cells" refers to yeast cells rich in membrane structures and subcellular compartments, which provide metabolic engineering and production of ideal hydrophobic environments for industrial products. In some embodiments, the oleaginous yeast cells are oleaginous yeast cells that utilize acetate for cell growth and product synthesis. For example, in some embodiments, the oleaginous yeast cells are Yarrowia lipolytica cells. Yarrowia lipolytica is a non-pathogenic oleaginous yeast that can use a variety of carbon sources, including organic acids, hydrocarbons, and various fats and oils. The term "oleaginous" refers to a microorganism that can accumulate more than 20% of its dry cell weight as lipids (see C. Ratledge et al., Microbial routes to lipids. Biochem Soc Trans. December 1989; 17(6): 1139-41). Exemplary oleaginous cells include yeasts such as Yarrowia lipolytica, Candida 107, Rhodotorula glutinis, Rhodosporidium toruloides, Cryptococcus curvatus, Trichosporon pullulan, Lipomyces lipofer, Schwanniomyces occidentalis, and other species from the genera Yarrowia, Lipomyces, Rhodosporidium, and Cryptococcus; oleaginous bacteria such as Rhodococcus, Acinetobacter, and Streptomyces; and oleaginous algae and microalgae.

[0078] Aspects of the present disclosure relate to genetically modified yeast cells (modified cells) comprising: a heterologous gene, wherein the heterologous gene encodes an enzyme having β-galactosidase (LacA) activity; one or more heterologous genes encoding one or more enzymes capable of converting lactate into pyruvate; one or more heterologous genes encoding one or more enzymes of the Leloir pathway; and one or more heterologous genes encoding one or more enzymes of the mevalonate pathway. In some embodiments, the modified cell is an oleaginous yeast cell. In some embodiments, the oleaginous cell is a Yarrowia lipolytica cell. In some embodiments, a polynucleotide comprising a gene is delivered to the cell. In some embodiments, the cell comprises a polynucleotide comprising a gene. In some embodiments, an enzyme encoded by a gene is delivered to the cell. In some embodiments, the cell comprises an enzyme encoded by a gene. In some embodiments, the gene is a heterologous gene. In some embodiments, the polynucleotide is a heterologous polynucleotide. In some embodiments, the enzyme is a heterologous enzyme. The term "heterologous" as used herein can be used interchangeably with the term "recombinant" and the term "exogenous". A heterologous gene, polynucleotide or enzyme refers to a gene, polynucleotide or enzyme that has been introduced or expressed in a host cell. A heterologous gene is a gene that has been introduced into a host cell or expressed in a host cell. A heterologous polynucleotide is a polynucleotide that has been introduced into a host cell or expressed in a host cell. A heterologous enzyme is an enzyme that has been introduced into a host cell or expressed in a host cell. In some embodiments, a heterologous gene, polynucleotide or enzyme is from an organism or species different from the host cell. In some embodiments, a heterologous gene, polynucleotide or enzyme is a synthetic gene, polynucleotide or enzyme. In some embodiments, a heterologous gene, polynucleotide or enzyme is an additional copy of a gene, polynucleotide or enzyme endogenously expressed in a host cell. In some embodiments, a heterologous gene can be modified by mutation. The term "mutation" as used herein refers to a change, alteration or modification of nucleotides in a nucleic acid compared to a wild-type sequence. For example, but not limited to, a mutation may include substitution, insertion, deletion or any combination thereof. In some embodiments, there is at least one mutation. In some embodiments, there are more than one mutation. In some embodiments, when there are more than one mutation, the mutation is different (e.g., not of the same type (e.g., substitution, insertion, deletion)). In some embodiments, when more than one mutation is present, the mutations are the same (eg, not the same type (eg, substitution, insertion, deletion)). Additionally, in some embodiments, the mutations result in a frameshift.

[0079] As mentioned above, mutation is a region (e.g., fragment, part, nucleobase, nucleoside, nucleotide) different from its wild-type nucleic acid in a given nucleic acid (e.g., DNA, RNA), and is most often reflected in each chain of nucleic acid. That is, when there is a mutation in a sample, it and its complementary sequence (complement) will be observed in each chain of nucleic acid during sequencing. However, when considering that a sample may include a single-stranded portion (e.g., gap, overhang) or may cause a region (e.g., gap) where a chain is resynthesized, this causes a problem. This problem is caused because, if there is a damaged base in such a single-stranded region or other regions synthesized anew, the damaged base can indicate the synthesis of its complementary chain, to include a base (because the damaged base can affect non-standard base pairing) that is not initially present in the nucleic acid from which the sample is produced. If a chain includes mismatched bases, the same situation may also occur. In this case, mismatching will show the pairing match in the resynthesized complementary sequence, rather than its natural mismatched base. When this occurs, the sequencing of the two chains will read the mutation in each chain, thereby showing the mutation, but this mutation may not be a true reflection of the original nucleic acid. Such mutations are referred to herein as “pseudo-mutations.” Pseudo-mutations are mutations that result from de novo synthesis of a complementary strand of a nucleic acid that is not representative of the original (eg, native, wild-type) complementary strand of the nucleic acid from which the sample was obtained.

[0080] The terms "wild type" and "native" are used interchangeably herein, are terms of expertise understood by those of skill in the art, and refer to the typical form of an article, organism, strain, gene or trait found in nature, as distinguished from engineered, mutated or variant forms.

[0081] In some embodiments, one or more heterologous genes encoding one or more enzymes capable of converting lactate to pyruvate are selected from the group consisting of lactate transporter (JEN1) and lactate dehydrogenase (LDH). In some embodiments, one or more heterologous genes encoding one or more enzymes of the Leloir pathway are selected from the group consisting of GAL10M, GAL1, GAL7, and GAL10E.

[0082] The Leloir pathway is a metabolic pathway known in the art. Cells utilize the Leloir pathway to decompose D-galactose. The term "catabolism" as used herein refers to the metabolic process of breaking down complex molecules (e.g., D-galactose) in an organism to form simpler molecules (e.g., glucose-1-phosphate). One of ordinary skill in the art will appreciate that the Leloir pathway converts galactose into glucose-1-phosphate, in particular through the enzymatic activity of GAL10M, GAL1, GAL7, and GALE. In some embodiments, the Leloir pathway is used to produce pyruvate in modified cells.

[0083] In some embodiments, the one or more heterologous genes encoding one or more enzymes of the mevalonate pathway are selected from the group consisting of geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (CarRP) and phytoene desaturase (CarB). In some embodiments, the GGPPS is GGPPSxd from Phaffia, GGPPSsa from Sulfolobus acidocaldarius, GGPPStc from Taxus canadensis, GGPPSpa from Pantoea agglomerans, GGPPSyl from Yarrowia lipolytica.

[0084] Mevalonic acid (MVA) pathway is another metabolic pathway known in the art. The MVA pathway is also referred to as the isoprenoid pathway or the HMG-CoA reductase pathway, and is an essential metabolic pathway that produces isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAP) from acetyl-CoA in particular. In some embodiments, IPP and DMAP in the MVA pathway are further metabolized to farnesyl diphosphate (FPP). In some embodiments, FPP in the MVA pathway is further metabolized to geranyl geranyl pyrophosphate (GGPP) by GGPP (e.g., GGPPSxd, GGPPSsa, GGPPStc, GGPPSpa, GGPPSyl). In some embodiments, GGPP in the MVA pathway is further metabolized to phytoene by CarRP. In some embodiments, phytoene in the MVA pathway is further metabolized to lycopene by CarB.

[0085] In some embodiments, the modified cell further comprises a heterologous gene encoding an enzyme having lycopene beta cyclase activity. The amino acid sequence of lycopene beta cyclase is provided herein as SEQ ID NO: 1:

[0086] MLLTYMEVHLYYTLPVLGVLSWLSRPYYTATDALKFKFLTLVAFTTASAWDNYIVYHKAWSYCPTCVTAVIGYVPLEEYMFFIIMTLLTVAFTNLVMRWHLHSFFIRPETPVMQSVLVRL VPITALLITAYKAWHLAVPGKPLFYGSCILWYACPVLALLWFGAGEYMMRRPLAVLVSIALPTLFLCWVDVVAIGAGTWDISLATSTGKFVVPHLPVEEFMFFALINTVLVFGTCAI(SEQ ID NO:1)

[0087] In some embodiments, the enzyme having lycopene beta cyclase activity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 1. The terms "percent identity", "sequence identity", "% identity", "% sequence identity" and "% identical" are used interchangeably herein and refer to a quantitative measure of the similarity between two sequences (e.g., nucleic acids or amino acids). The percent identity of genomic DNA sequences, intron and exon sequences, and amino acid sequences between humans and other species varies by species type, with chimpanzees having the highest percent identity to humans among all species in each category.

[0088] For example, the percent identity of two nucleic acid sequences can be calculated by aligning the two sequences for optimal comparison (e.g., gaps can be introduced in one or both of the first and second nucleic acid sequences for optimal alignment, and non-identical sequences can be ignored for comparison purposes). In certain embodiments, the length of the sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0089] The comparison of sequences and the determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using methods such as described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, AM and Griffin, HG, ed., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., ed., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Alternatively, the GAP program in the GCG software package can be used to determine the percent identity between two nucleotide sequences using the NWSgapdna.CMP matrix. Commonly used methods for determining percent identity between sequences include, but are not limited to, the methods disclosed in Carillo, H. and Lipman, D., SIAM J Applied Math., 48: 1073 (1988) (incorporated herein by reference). Techniques for determining identity have been incorporated into publicly available computer programs. Exemplary computer software for determining homology between two sequences include, but are not limited to, the GCG program package, Devereux, J. et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, SF et al., J. Molec. Biol., 215, 403 (1990)).

[0090] When reciting percent identity or ranges thereof (e.g., at least, greater than, etc.), unless otherwise specified, the endpoints are inclusive and a range (e.g., at least 70% identity) is inclusive of all ranges within the cited range (e.g., at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 111%, at least 112%, at least 113%, at least 114%, at least 115%, at least 116%, at least 117%, at least 118%, at least 119%, at least %, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9% identity) and all increments thereof (e.g., one tenth of a percentage point (e.g., 0.1%), one hundredth of a percentage point (e.g., 0.01%), etc.).

[0091] In some embodiments, lycopene beta cyclase (SEQ ID NO: 1) is modified or mutated to increase or decrease enzyme activity. In some embodiments, the enzyme having lycopene beta cyclase activity comprises an amino acid sequence as shown in any one of SEQ ID NO: 2-4. In some embodiments, the following amino acid substitutions are included relative to SEQ ID NO: 1: Y27R; V175W; T31R; F92W; or T31R and F92W.

[0092] The amino acid sequence of one such modified lycopene beta cyclase activity is provided herein as SEQ ID NO: 2:

[0093] MLLTYMEVHLYYTLPVLGVLSWLSRPRYTATDALKFKFLTLVAFTTASAWDNYIVYHKAWSYCPTCVTAVIGYVPLEEYMFFIIMTLLTVAFTNLVMRWHLHSFFIRPETPVMQSVLVRL VPITALLITAYKAWHLAVPGKPLFYGSCILWYACPVLALLWFGAGEYMMRRPLAVLVSIALPTLFLCWVDVVAIGAGTWDISLATSTGKFVVPHLPVEEFMFFALINTVLVFGTCAI(SEQ ID NO:2)

[0094] The amino acid sequence of another such modified lycopene beta cyclase activity is provided herein as SEQ ID NO: 3:

[0095] MLLTYMEVHLYYTLPVLGVLSWLSRPYYTATDALKFKFLTLVAFTTASAWDNYIVYHKAWSYCPTCVTAVIGYVPLEEYMFFIIMTLLTVAFTNLVMRWHLHSFFIRPETPVMQSVLVRL VPITALLITAYKAWHLAVPGKPLFYGSCILWYACPVLALLWFGAGEYMMRRPLAWLVSIALPTLFLCWVDVVAIGAGTWDISLATSTGKFVVPHLPVEEFMFFALINTVLVFGTCAI(SEQ ID NO:3)

[0096] The amino acid sequence of yet another such modified lycopene beta cyclase activity is provided herein as SEQ ID NO:4:

[0097] MLLTYMEVHLYYTLPVLGVLSWLSRPYYTARDALKFKFLTLVAFTTASAWDNYIVYHKAWSYCPTCVTAVIGYVPLEEYMFFIIMTLLTVAWTNLVMRWHLHSFFIRPETPVMQSVLVRL VPITALLITAYKAWHLAVPGKPLFYGSCILWYACPVLALLWFGAGEYMMRRPLAVLVSIALPTLFLCWVDVVAIGAGTWDISLATSTGKFVVPHLPVEEFMFFALINTVLVFGTCAI(SEQ ID NO:4)

[0098] In some embodiments, the modified cell further comprises heterologous genes encoding tHMGR, ERG12, IDI and ERG20 of the mevalonic acid (MVA) pathway, and / or choline kinase (CK) and isopentenyl phosphate kinase (IPK). In some embodiments, the modified cell further comprises: a heterologous gene encoding an enzyme having β-carotene ketolase (CrtW) activity; and a heterologous gene encoding an enzyme having β-carotene hydroxylase (CrtZ) activity. In some embodiments, an enzyme having CrtW activity is fused to an enzyme having CrtZ activity. In some embodiments, the CrtW / CrtZ fusion enzyme comprises a localization signal. In some embodiments, the localization signal targets the CrtW / CrtZ fusion enzyme to the endoplasmic reticulum, peroxisome and / or liposome. As used herein, the term "fusion enzyme" refers to an enzyme protein comprising two or more separate proteins. In some embodiments, the fusion enzyme is produced by connecting two or more genes that originally encode separate proteins. In some embodiments, two or more genes connected together are translated into a single protein or enzyme. The term "localization signal" refers to a peptide fragment expressed on a protein of interest that mediates the transport of the protein to a target location within or outside the cell. In some embodiments, the localization signal is a short peptide fragment. In some embodiments, the localization signal targets the protein to the endoplasmic reticulum. In some embodiments, the localization signal targets the protein to the peroxisome. In some embodiments, the localization signal targets the protein to the lipid body of the cell.

[0099] In some embodiments, the modified cell further comprises a heterologous gene encoding an enzyme having lycopene beta cyclase activity and / or a heterologous gene encoding an enzyme having lycopene epsilon cyclase activity. In some embodiments, the modified cell further comprises a heterologous gene encoding an enzyme having carotenoid hydroxylase 1 (LUT1) activity and / or a heterologous gene encoding an enzyme having carotenoid hydroxylase 5 (LUT5) activity.

[0100] Another aspect of the present disclosure relates to a genetically modified yeast cell (modified cell) comprising: a first heterologous gene, wherein the first heterologous gene encodes an enzyme having β-carotene ketolase (CrtW) activity; and a second heterologous gene, wherein the second heterologous gene encodes an enzyme having β-carotene hydroxylase (CrtZ) activity; wherein the modified cell produces β-carotene. In some embodiments, the modified cell is an oleaginous yeast cell. In some embodiments, the oleaginous cell is a Yarrowia lipolytica cell. In some embodiments, the enzyme having CrtW activity is fused to an enzyme having CrtZ activity. In some embodiments, the CrtW / CrtZ fusion enzyme comprises a localization signal. In some embodiments, the localization signal targets the CrtW / CrtZ fusion enzyme to the endoplasmic reticulum, peroxisomes and / or lipid bodies.

[0101] Another aspect of the present disclosure relates to a method for converting a carbon source into lycopene and / or beta-carotene, the method comprising: contacting a modified cell as described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into lycopene and / or beta-carotene. In some embodiments, the carbon source is acid whey. In some embodiments, the carbon source is converted into lycopene. In some embodiments, the carbon source is converted into beta-carotene. As used herein, the term "carbon source" refers to any natural or artificial carbon source, such as carbon dioxide, methane, or acid whey.

[0102] Another aspect of the present disclosure relates to a method of converting a carbon source into astaxanthin, the method comprising: contacting a modified cell described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into astaxanthin. In some embodiments, the carbon source is acid whey.

[0103] Another aspect of the present disclosure relates to a method of converting a carbon source into alpha-carotene, the method comprising: contacting a modified cell described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into alpha-carotene. In some embodiments, the carbon source is acid whey.

[0104] Another aspect of the present disclosure relates to a method of converting a carbon source into lutein, the method comprising: contacting a modified cell described herein with a carbon source; and incubating the modified cell with the carbon source for a sufficient time to convert the carbon source into lutein. In some embodiments, the carbon source is acid whey.

[0105] Another aspect of the present disclosure relates to an enzyme having lycopene β cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 2. Another aspect of the present disclosure relates to an enzyme having lycopene β cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 3. Another aspect of the present disclosure relates to an enzyme having lycopene β cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 4.

[0106] The following description sets forth the details of one or more embodiments of the methods and products disclosed herein. Other features or advantages of the methods and products disclosed herein will be apparent from the following drawings and detailed description of several embodiments and also from the appended claims.

[0107] The terms "approximately" or "about" are used interchangeably herein and, when applied to one or more values ​​of interest, refer to values ​​similar to the reference values ​​recited. In certain embodiments, the terms "approximately" or "about" refer to a range of values ​​that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the reference value recited in either direction (i.e., a percentage greater than or a percentage less than), unless otherwise specified or apparent from the context (e.g., when the number exceeds 100% of the possible values).

[0108] The words and terms used in this application are for descriptive purposes only and should not be considered as limiting. Terms used in this application, such as "includes," "comprising," "having," "containing," "involving," and / or variations thereof, are intended to encompass the items listed thereafter and their equivalents as well as additional items.

[0109] The methods and products disclosed herein are further illustrated by the following examples, which are in no way to be construed as further limiting. The entire contents of all references cited throughout this application (including literature references, granted patents, published patent applications, and co-pending patent applications) are expressly incorporated herein by reference. Example

[0110] In order to more fully understand the methods and products described in this application, the following examples are set forth. The examples described in this application are used to illustrate the systems and methods provided in the present disclosure and should not be interpreted in any way as limiting the scope thereof.

[0111] Example 1. Microbial engineering to produce carotenoids from acid whey

[0112] This example relates to engineering the oleaginous yeast Yarrowia lipolytica to overproduce carotenoids from acid whey and / or animal feeds with different compositions of oil and protein as needed. It has been previously shown that the expression of secretory extracellular β-galactosidase and the expression of genes for accelerating the native galactose metabolic pathway enable Yarrowia lipolytica to consume all sugars in AW (Mano et al., 2020). This article describes the optimal gene combination for lycopene synthesis and two independent strategies that almost completely bypass substrate inhibition during the β-carotene synthesis process. Substrate inhibition is undesirable in industrial applications of microorganisms for product synthesis. Although a variety of methods have been explored to address this limitation, such as enzyme immobilization, two-phase distribution bioreactor systems, batch substrate feeding strategies, and protein engineering, most of these solutions are limited to systems with inhibition caused by the starting substrate and are difficult to apply to the context of chemically produced microbial engineering. It is worth noting that these strategies were initially demonstrated in carotenoid-producing strains of Yarrowia lipolytica using glucose as a carbon source. Subsequently, the results indicated that yeast cell engineering was used to effectively produce carotenoid compounds from AW.

[0113] Biosynthesis of β-carotene and lycopene from glucose

[0114] First, structure-guided protein design, combined with phylogenetic information, was used to generate protein variants with reduced inhibition. For example, a single mutation in the lycopene cyclase gene was identified that completely abolished substrate inhibition without reducing enzyme activity, which resulted in a significant increase in β-carotene production. The synthesis of β-carotene in Yarrowia lipolytica requires heterologous expression of three genes encoding phytoene synthase, phytoene dehydrogenase, and lycopene cyclase. Geranylgeranyl diphosphate synthase (GGPPS) was also considered because it controls flux toward carotenoid rather than sterol synthesis. The relevant gene was derived from a eukaryotic organism and was introduced into a TRP1-disrupted Yarrowia lipolytica po1f strain.

[0115] The second approach was to produce similar β-carotene titers and selectivity by reducing carbon flux through the carotenoid pathway and thus preventing inhibitory metabolites from accumulating to inhibitory levels, in contrast to the traditional pathway engineering paradigm. This was achieved by establishing a metabolic valve mediated by geranylgeranyl pyrophosphate synthase (GGPPS) that regulates the rate of substrate lycopene formation, which effectively alleviates substrate inhibition. Although this approach reduces flux through the target pathway, the gains from suppressing substrate levels and thus maintaining high enzyme activity more than compensate for any productivity losses caused by the flux diversion.

[0116] It was also noted that by altering the activity of GGPPS in vivo, the product profile of β-carotene and lycopene could be altered. The high activity of GGPP could be exploited to reconstruct a specialized lycopene-producing strain. Combining this idea with a specific lycopene cyclase variant, high concentrations of lycopene were successfully produced with undetectable amounts of β-carotene. Lycopene production was additionally increased by overexpressing the MVA pathway and introducing an IUP with glucose as a substrate.

[0117] Previous studies have established that the lipophilic nature of carotenoids promotes their storage in cellular lipid bodies. Larroude et al. found that an engineered lipid overproducing strain was able to produce more β-carotene, with a titer of 6.5 g / L, while producing 42.6 g / L lipid (Larroude et al., 2018). While providing a compatible compartment for hydrophobic isoprenoid accumulation, de novo formation of TAGs also consumes a large amount of carbon source, resulting in limited acetyl-CoA flux into the MVA (product formation pathway). This study demonstrates that the native TAG accumulation capacity of Yarrowia lipolytica is sufficient for carotenoid sequestration. Balancing the flux distribution between carotenoid and lipid synthesis through C / N ratio adjustment retains a larger portion of the acetyl-CoA pool for carotenoid production, thereby achieving higher titers and per cell content.

[0118] In addition, it was demonstrated that carotenoid biosynthesis is supported by cellular lipid degradation during the glucose depletion stationary phase. In fermentation experiments using glucose as a substrate, it was found that the content of β-carotene continued to rise during the stationary phase even after the glucose in the culture medium had been depleted. Throughout the fermentation process, the lipid content initially increased, reaching a maximum on the third day, after which the lipid content rapidly decreased when the glucose was completely consumed. However, despite the reduction in lipid content, the β-carotene content continued to rise well after the glucose depletion point, indicating that TAG was used to maintain metabolic activity and carotenoid synthesis. When glucose was still present during the first 3 days, the intracellular lipid droplets gradually aggregated into liposomes, which sequestered the produced β-carotene. However, it was clear that the liposomes were no longer visible in the late fermentation period due to TAG decomposition, which in turn caused the accumulated β-carotene to be more dispersed throughout the cell. It is shown that acetyl-CoA formed by β-oxidation can support the MVA pathway and ultimately promote β-carotene formation. Therefore, this may be a mechanism for cells to convert TAG to carotenoids during the glucose depletion stationary phase.

[0119] Biosynthesis of β-carotene and lycopene from AW

[0120] After obtaining results for carotenoid synthesis using glucose as substrate, a strain of Yarrowia lipolytica was constructed that completely consumes all organic molecules found in AW and produces high concentrations of lycopene. The engineering work included the introduction of genes responsible for lactose degradation, galactose uptake, highly active GGPP, phytoene dehydrogenase, and a bifunctional phytoene synthase / lycopene cyclase of eukaryotic origin with a single mutation that abolished the cyclase activity. By balancing the flux distribution between lycopene and lipid synthesis through C / N ratio adjustment, a maximum lycopene concentration of about 3 g / L was achieved using untreated AW as substrate, with 0.230 mg of lycopene per gram of dry cell weight. The engineered strain was also able to consume concentrated AW. After 14 days, all sugars and organic acids in AW were consumed en bloc, resulting in a maximum lycopene concentration of 13.4 g / L.

[0121] Biosynthesis of Astaxanthin

[0122] Another high-value carotenoid-derived pigment is astaxanthin. Astaxanthin has been the subject of increasing interest due to its wide range of applications in food, animal feed, nutraceuticals, cosmetics, and pharmaceutical industries. These applications are attributed to its strong antioxidant, anti-inflammatory, and anticancer activities.

[0123] A downstream astaxanthin biosynthetic pathway from β-carotene was constructed by expressing the CrtW gene encoding β-carotene ketolase and the CrtZ gene encoding β-carotene hydroxylase. To further improve the heterologous pathway, β-carotene ketolase and hydroxylase were obtained from different organisms. Given that the main natural sources of astaxanthin synthesis are bacteria and algae, additional CrtW and CrtZ were specifically screened from such organisms, and the CrtW / Z pair that maximized microbial astaxanthin production using β-carotene overproducing strains was identified. Furthermore, it was determined that increasing the physical proximity between CrtW and CrtZ minimizes the substrate-enzyme distance and increases the reaction rate. To this end, an active fusion between the CrtW and CrtZ enzymes was created with the goal of enhancing the contact of the product / precursor with the respective enzymes by creating a closer microenvironment. The fusion enzyme produced astaxanthin with higher efficiency compared to the individual enzymes. Finally, the expression of the fusion enzyme was investigated when targeted to various subcellular compartments. Initially, the fusion enzyme CrtW-Z was targeted to liposomes (LB) by linking them to an oleosin sequence, providing an alternative biological pathway for astaxanthin biosynthesis. The LB-targeted strain produced significantly higher astaxanthin titers than a control strain expressing the pathway in the cytosol. Targeting the fusion enzyme to other organelles, such as the endoplasmic reticulum and peroxisome, further improved astaxanthin titers from glucose, and simultaneous targeting to all three subcellular organelles produced even better results.

[0124] Other products

[0125] The results described herein demonstrate that the technology of engineered oleaginous yeast Yarrowia lipolytica is used to biosynthesize various high value-added products. The technology can also be used to produce other products from AW, such as lutein, α-carotene and other members of the isoprenoid pathway. Therefore, the present disclosure relates to a general method for upgrading dairy industry waste to a collection of high value-added products that are widely used as food ingredients.

[0126] Production of animal feed from AW

[0127] Protein production is a natural component of the yeast life cycle and can account for approximately 40% of dry weight under certain conditions (Yamada et al., 2005). Lipid production, on the other hand, depends on certain nutritional cues and is generally growth phase dependent (Goncalves et al., 2014). Early in fermentation, most energy and carbon are used for growth and cell division, but as essential nutrients begin to become depleted (especially nitrogen), cells stop dividing and instead begin to store excess carbon in the form of lipids, which are sequestered in large intracellular droplets. Under certain conditions, these lipid bodies can account for more than two-thirds of the cell dry weight at the end of fermentation (Qiao et al., 2015). In the case of AW, available nitrogen is primarily in the form of milk proteins, and Yarrowia's access to this nitrogen source can be altered to produce products with higher or lower lipid weight percentages.

[0128] The ratio of lipid to protein is controlled by utilizing engineered strains of Yarrowia. Two strains of Yarrowia were used; W29 (non-engineered), which produces a mixture of lipids and cell mass, and an engineered strain called ACC-DGA. The ACC-DGA strain is designed to produce more lipids via overexpression of native Yarrowia genes encoding enzymes involved in triacylglycerol biosynthesis (Tai et al., 2013; U.S. Patent Application No. US20130143282A1). These strains also differ in their ability to consume proteins present in AW. ACC-DGA secretes insufficient production of proteases and is therefore unable to degrade milk proteins. Starting from these two strains, a product with high fat, high protein, or a mixture of both was produced.

[0129] Example 2. Conversion of dairy industry waste into food and feed ingredients

[0130] To expand the AW utilization technology and transform it into a platform for producing valuable food and feed ingredients, an engineered Yarrowia lipolytica strain capable of producing lycopene was sought as a model compound for natural products from AW. It was observed that lycopene can subsequently serve as a precursor for other carotenoids such as α- and β-carotene, lutein, and astaxanthin ( Figure 2). Attempts to improve the production of β-carotene and astaxanthin have been previously reported, mainly by using the model microorganisms Escherichia coli and Saccharomyces cerevisiae. However, the recombinant production of α-carotene and lutein in fungi has not been reported. In addition, according to previous studies, the expression of secreted extracellular β-galactosidase and the expression of genes that accelerate the native galactose metabolic pathway were shown to enable Yarrowia lipolytica to consume all sugars in AW ( Figures 1A-1C and Figure 3 ). Therefore, this strain utilizing AW is an excellent starting point to serve as a chassis for subsequent engineering steps ( Figure 3 ).

[0131] To achieve this goal, first, the optimal combination of carotenoid biosynthetic enzymes that maximize carotenoid production and accumulation in Yarrowia cells will be determined. For further improvement, different subcellular localization strategies will be used to identify the optimal enzyme co-localization in subcellular organelles such as the endoplasmic reticulum, peroxisomes, and lipid bodies. Enzymes located in different subcellular compartments will have higher activity when converting substrates that are also located in the same compartment. Finally, the natural mevalonate pathway will be engineered by overexpressing the well-known rate-limiting enzyme to increase the supply of carotenoid precursors.

[0132] Reverse osmosis is commonly used to concentrate AW into smaller volumes to reduce waste disposal and transportation costs. High concentrations of lactic acid in concentrated AW can inhibit the growth of Yarrowia lipolytica. Therefore, methods will be sought to enhance the tolerance of Yarrowia lipolytica to lactic acid by overexpressing enzymes involved in lactic acid consumption. This approach can be supplemented by engineering oxidative stress defense pathways based on previous work in which lipid synthesis in Yarrowia lipolytica was improved (Xu et al., 2017). All constructed strains will be validated in larger volume bioreactors of 10 L. Another approach could be to explore the genome-wide response of Yarrowia lipolytica to concentrated AW, which will help understand the genomic basis of tolerance to concentrated AW. Transcriptional analysis will assess the genome-wide response and allow the identification of genes that are critical for conferring tolerance and the underlying mechanisms that enhance strain tolerance. Using the engineered strains described in the previous objectives as a starting point, a genome-wide evolution engineering strategy can be applied and mutants with enhanced tolerance can be isolated. Multi-omics analysis (genomics and transcriptomics) will be used to identify strain-specific genes and global gene expression differences in mutants and provide information for rational engineering of host strains.

[0133] In addition, TEA will be used to evaluate the potential feasibility of the proposed bioprocess and identify process and economic bottlenecks and targets for further research and improvement. The evaluation of the overall value of the proposed technology will provide useful information for potential investors. Process modeling will be performed using a process simulator. Environmental assessment of the proposed bioprocess is another aspect considered to identify and focus on bioprocess parameters that are critical to the environment (Heinzle et al., 1998).

[0134] Additional work also includes optimizing the fermentation process and purifying the carotenoid product. As intracellular products, carotenoids are sequestered within the cells and must be extracted and purified from the cell biomass. The extraction method may initially involve a pretreatment step that helps to disrupt the cell wall. Afterwards, carotenoids are typically extracted using organic solvents due to their lipophilic nature. The process may include washing steps, crystallization steps, and removal of solvent traces by vacuum drying. During the extraction of carotenoids, challenges are their sensitivity to excessive heat, light, acid, and long extraction times. However, it is worth noting that the isolation and purification of carotenoids are performed according to mature technologies that can be licensed and deployed in an integrated AW to carotenoids program.

[0135] Example 3. Targeting pathway expression to subcellular organelles improves astaxanthin synthesis in Yarrowia lipolytica

[0136] Engineering microorganisms to overproduce high-value natural products has primarily focused on manipulating metabolic pathways in the cytoplasm. Recently, there has been growing interest in directing metabolic pathways in subcellular organelles of yeast, thereby increasing local substrate and enzyme concentrations and enhancing the efficiency of compartmentalized pathways and the production of end products (Cao et al., 2020; Hammer and Avalos, 2017). Compared to the traditional model yeast Saccharomyces cerevisiae, systematic studies of cellular compartments for natural product biosynthesis in the oleaginous yeast Yarrowia lipolytica have lagged behind. This is the case despite the important role played by intracellular compartments of this yeast, such as the LB, ER, and peroxisomes. In this study, a heterologous metabolic pathway for astaxanthin synthesis was assembled using the fusion enzyme CrtW-Z and targeted expression in subcellular organelles of Yarrowia lipolytica. The present disclosure relates to tightly combining precursors for astaxanthin synthesis with enzymes that catalyze pathway reactions. Since Yarrowia lipolytica is widely regarded as a model organism for the production of acetyl-CoA-derived compounds (Abdel-Mawgoud et al., 2018), other products derived from the same precursor could also benefit from this study.

[0137] The first round of experiments took advantage of the lipophilic properties of β-carotene, the main precursor for astaxanthin synthesis, and targeted the lipophilic compartment of the lipid body for astaxanthin pathway expression. After the successful implementation of this strategy, the compartment for β-carotene synthesis, the ER, was targeted next, and this further improved production. Finally, the peroxisome was also targeted for compartmentalization due to its role as a storage space for lipophilic compounds. Targeting the astaxanthin pathway to all three compartments produced the best results in terms of product accumulation, indicating that placing the astaxanthin pathway near the β-carotene precursor and providing a suitable vehicle for astaxanthin storage are both important for enhancing product accumulation in Yarrowia lipolytica. Simultaneous targeting of the CrtW-Z-dependent pathway to the LB, ER, and peroxisomes produced the highest astaxanthin titers reported in yeast to date. Therefore, exploiting subcellular organelles could be a promising approach to further enhance isoprenoid biosynthesis due to their potential advantages in improving precursor supply and cofactor availability.

[0138] Overall, the present disclosure has successfully explored enzyme fusion and its compartmentalization in subcellular organelles, effectively directing substrates or intermediates to the final product. These methods represent one of the first approaches to develop yeast subcellular factories. Hydrophobicity is a key property for engineering astaxanthin pathways, but other molecular features may also be explored when designing future applications of organelle engineering.

[0139] Screening of β-carotene ketolase and hydroxylase enzyme combinations

[0140] The astaxanthin biosynthetic pathway has been extensively studied and well characterized. Figure 4 As shown, glucose is converted into the precursor isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP) through glycolysis and the mevalonate (MVA) pathway. Subsequently, IPP and DMAPP are concentrated by GGPP synthase to form geranylgeranyl diphosphate (GGPP). GGPP is then converted to astaxanthin by a heterologous enzyme that constitutes the downstream pathway from GGPP to astaxanthin. Therefore, the heterologous pathway for astaxanthin synthesis can be divided into two modules: an upstream module from GGPP to β-carotene and a downstream module from β-carotene to astaxanthin ( Figure 4). In previous studies, a strain of Yarrowia lipolytica was engineered so that the upstream pathway was able to overproduce β-carotene. This was achieved by introducing genes of the β-carotene biosynthetic pathway into Yarrowia lipolytica po1f: the genes for the GGPP synthase from Sulfolobus acidocaldarius (GGPPsa), the bifunctional enzyme phytoene synthase / lycopene β-cyclase (CarRP), and the gene for the phytoene dehydrogenase (CarB) from Mucor circinelloides. In this β-carotene-producing strain, the auxotrophic marker was removed by the Cre-loxP system, allowing for the next round of genomic integration. Thus, a chassis host strain capable of overproducing β-carotene, a substrate for astaxanthin synthesis, was obtained. The downstream astaxanthin biosynthesis pathway from β-carotene was constructed by expressing the CrtW gene encoding β-carotene ketolase and the CrtZ gene encoding β-carotene hydroxylase, which respectively perform the addition of two ketone moieties and hydroxyl groups, causing the colony color to change from yellow to red. Figure 5A ). Compared to the titer of astaxanthin, the β-carotene titer obtained by heterologous expression of CrtZ / W was much higher, indicating that β-carotene ketolysis and hydroxylation are the rate-limiting steps in astaxanthin synthesis (Kildegaard et al., 2017). In a first attempt to construct an astaxanthin pathway, CrtW from the marine bacterium Paracoccus sp. (PsCrtW) and CrtZ from the Enterobacteriaceae Pantoea ananatis (PaCrtZ) (Kildegaard et al., 2017) were introduced into the β-carotene-producing strain YL00. After 72 h of cultivation, this produced 6.1 mg / L of astaxanthin ( Figure 5B ). Low production may be due to an imbalance in enzyme activities leading to intermediate accumulation. It has been recognized that bacterial CrtW and CrtZ can utilize β-carotene and its keto and hydroxylation products as substrates, resulting in different carotenoid intermediate profiles, which can greatly affect astaxanthin production and productivity (Chang et al., 2015; Choi et al., 2005; Wang et al., 2017). Therefore, an optimal combination of β-carotene ketolase and hydroxylase activities is crucial for enhanced astaxanthin accumulation due to substrate preference and unbalanced enzyme activities.

[0141] To further improve the heterologous pathway, β-carotene ketolases and hydroxylases were obtained from different organisms. Given that the main natural sources of astaxanthin synthesis are bacteria and algae, two additional CrtWs and two CrtZs were specifically screened from these organisms (Table 1). To identify the CrtW / Z pairs that maximize microbial astaxanthin production, a combinatorial screen of three CrtWs and three CrtZs was performed in β-carotene overproducing strains. The astaxanthin titers obtained using the various engineered strains ranged from 3.2 to 9.9 mg / L ( Figure 5B ), indicating that balanced enzyme activity is essential for reestablishing an efficient astaxanthin production pathway. The best combination of CrtW / Z that produced the highest astaxanthin production was CrtW / Z from PsCrtW / HpCrtZ ( Figure 5B ). Notably, all strains containing PsCrtW showed significantly better performance than strains containing the other two CrtWs ( Figure 5B ). In addition, the enzyme HpCrtZ from a eukaryotic organism was well expressed in Yarrowia lipolytica for the first time and resulted in high levels of astaxanthin production ( Figure 5B ).

[0142] Enhanced astaxanthin production by fusion enzymes

[0143] Depending on the order in which ketolysis and hydroxylation reactions are performed during the biosynthesis of β-carotene to astaxanthin, several intermediates are synthesized, resulting in multiple pathways from β-carotene to the final product ( Fig. 6A ). Although the engineered strain YL02 containing an optimized combination of CrtW and CrtZ improved astaxanthin production, higher levels could probably be achieved by converting other equally accumulated intermediates, especially echinone, canthaxanthin, and zeaxanthin ( Figure 6B ). The nature of the accumulated intermediates suggests that the conversion of canthaxanthin or zeaxanthin to astaxanthin is a pathway bottleneck. It is hypothesized that these bottlenecks are caused by low metabolite concentrations near the CrtZ / CrtW enzymes and can therefore be removed by shortening the distance between the enzymes and their substrates. Increasing the physical proximity between CrtW and CrtZ can minimize the substrate-enzyme distance and increase the reaction rate. To test this hypothesis, an active fusion was created between the CrtW and CrtZ enzymes with the goal of enhancing the contact of the product / precursor with the respective enzymes by creating a tighter microenvironment.

[0144] β-Carotene ketolase (PsCrtW) from Paracoccus sp. and β-carotene hydroxylase (HpCrtZ) from Haematococcus pluvialis were selected to create the fusion enzyme based on their high activity in producing more astaxanthin when expressed alone ( Figure 5BThe two proteins were expressed as a translational fusion separated by a linker spacer that was introduced to keep the two enzymes in close proximity and at the same time allow interaction between the domains (Nogueira et al., 2019). Both constructs were studied by expressing the fusions separately as well as their controls in the β-carotene overproducing strain YL00 ( Figure 6C The levels of astaxanthin and intermediates in the engineered strains were measured and it was shown that both engineered strains expressing the CrtZ-W or CrtW-Z enzyme fusions could produce increased amounts of astaxanthin ( Figure 6C and Fig. 9 ), indicating that the two fusion enzymes function similarly, but are more active than the corresponding single expressed enzymes. Compared with the control strain containing the single enzymes CrtW+Z, the astaxanthin production of the fusion enzyme strains was significantly improved, and increased by 2.2 times in the fusion CrtZ-W strain to 22.8 mg / L, and increased by 2.8 times in the fusion CrtW-Z strain to 28.9 mg / L ( Figure 6C This provides support for the hypothesis that the significant improvement of the fusion enzyme strain may be due to improved local substrate-enzyme proximity and its interaction. Interestingly, the strain expressing the CrtW-Z fusion showed enhanced performance over the strain with the CrtZ-W fusion enzyme ( Figure 6C ), which suggests that the catalytic activity may be higher when CrtW is located at the N-terminus of the fusion enzyme. It should be noted that the metabolite profiles of the fusion enzyme strain are different from those of the individual enzymes. The accumulation of intermediates in the fusion enzyme strain is reduced, especially canthaxanthin and zeaxanthin ( Figure 6B and Fig. 9 ). This suggests that the fusion enzyme conferred a faster conversion of canthaxanthin and zeaxanthin to astaxanthin. Unexpectedly, the intermediate 3'-hydroxyechinone accumulated significantly in the fusion enzyme strain ( Figure 6B and Fig. 9 ). Although the fusion enzyme was more efficient in producing astaxanthin compared to the individual enzymes, the accumulation of intermediates was not effectively addressed. Therefore, a significant challenge is to explore methods to maximize the flux from β-carotene to astaxanthin synthesis without the accumulation of intermediates.

[0145] Targeting enzyme fusions to subcellular compartments to enhance astaxanthin biosynthesis

[0146] Chromatographic profile of carotenoids synthesized by a strain containing the fusion enzyme CrtW-Z ( Figure 6B) showed that the precursor β-carotene together with the accumulated ketocarotenoid intermediates (echinone, 3'-hydroxyechinone and zeaxanthin) hindered the carbon flux towards astaxanthin synthesis. In order to reduce the formation of these intermediates, the effect of increasing the copy number of the astaxanthin biosynthetic pathway was examined by introducing an additional copy of the fusion enzyme CrtW-Z into the astaxanthin producing strain YL11 (producing strain YL12). However, this did not affect the amount of astaxanthin produced ( Fig. 10A ), and intermediate accumulation is largely unresolved ( Fig. 10B ). This led to the hypothesis that the inefficient production of astaxanthin could be due to the precursor β-carotene being sequestered within lipid droplets, where cytosolic enzymes cannot easily access it and convert it to astaxanthin.

[0147] Liposomes (LB) in Yarrowia lipolytica do create hydrophobic pockets that can preferentially sequester lipophilic isoprenoid compounds. Since the astaxanthin precursor β-carotene is such a lipophilic molecule, its sequestration in LB was investigated ( Fig.11 ) could affect astaxanthin production. It was hypothesized that targeting the astaxanthin pathway to LB would accelerate the conversion of β-carotene to astaxanthin due to the greater physical proximity between the enzyme and substrate. To this end, a well-characterized N-terminal localization signal that enables targeting of proteins to LB was utilized (Yang et al., 2019). The fusion enzyme CrtW-Z was targeted to LB by linking it to the protein localization tag oleosin sequence ( Fig. 7A ), thus providing an alternative biological pathway for astaxanthin biosynthesis. As expected, the targeted LB strain YL13 produced an astaxanthin titer of 46.8 mg / L, which was a 1.62-fold increase compared to the control strain expressing the pathway in the cytoplasm ( Fig.7D Most notably, the accumulation of β-carotene and ketocarotenoid intermediates was reduced ( Figure 7B-7C ).

[0148] Inspired by these results, we explored the site of β-carotene synthesis in cells. Prediction of transmembrane helices of heterologous proteins related to β-carotene biosynthesis (GGPPsa, CarB, and CarRP) revealed that except for GGPPsa, the other two enzymes have transmembrane helices ( Figures 12A-12C ), which indicates that CarB and CarRP are located in subcellular organelles. In order to investigate the subcellular localization sites of the three proteins, fluorescence analysis of colocalization of the fusion proteins with GFP was used, and it was found that both CarB and CarRP were located at the endoplasmic reticulum (ER), while GGPPsa was located in the cytoplasm ( Fig.13 This suggests that β-carotene biosynthesis occurs primarily in the ER, unlike triacylglycerol (TAG), which is synthesized in the ER and further aggregated in the LB ( Fig. 7A)) (Xu et al., 2016). Therefore, the ER would provide an additional potential target for compartmentalization of the astaxanthin pathway.

[0149] In addition to LB and ER, another organelle that potentially affects the accumulation of intracellular β-carotene is the peroxisome, which also acts as a storage compartment for lipophilic compounds (Liu et al., 2020). Therefore, as expressed by the fusion enzyme CrtW-Z, the astaxanthin pathway was targeted to the ER and peroxisome by fusion with the well-characterized targeting sequences KDEL and SKL, respectively. Fig. 7A As expected, the corresponding organelle-targeted strains significantly increased astaxanthin titers compared to the cytosolic pathway-expressing strains ( Figures 7B-7D Strain YL14, which contains an engineered ER-targeted pathway, produced 53.2 mg / L of astaxanthin after 72 h of culture, representing a 1.84-fold increase relative to its cytosolic counterpart ( Fig.7D The corresponding peroxisome-targeted strain YL15 produced about 58.7 mg / L of astaxanthin, which was 2.03 times higher than that of the strain YL11 with cytosolic expression ( Fig.7D ).

[0150] Considering that a significant fraction of the β-carotene pool is located in the ER, LB, and peroxisomes, targeting the pathway to more than one compartment was investigated. It was found that when the fusion enzyme CrtW-Z was simultaneously targeted to both the LB and the ER, astaxanthin titers were significantly increased compared to single subcellular compartmentalization ( Fig.7D ). It is noteworthy that the bottleneck represented by the accumulation of β-carotene and ketocarotenoid intermediates was effectively alleviated ( Figures 7B-7D In addition, in the triple organelle engineered strain YL17 with an additional CrtW-Z located at the peroxisome, the astaxanthin titer was further increased to 139.4 mg / L ( Fig.7D ). Taken together, these results support that compartmentalization not only renders intermediates accessible to downstream engineered biocatalysts but also enhances the catalytic activity of enzymes due to the unique physicochemical environment.

[0151] Optimizing fermentation conditions to maximize the conversion of β-carotene to astaxanthin

[0152] Next, the effect of medium composition on astaxanthin production was investigated. The glucose concentration was varied while keeping the nitrogen content constant, effectively changing the C / N ratio of the medium. Dramatic changes in astaxanthin production were observed depending on the initial glucose concentration. It was found that astaxanthin titer gradually increased with increasing glucose concentration and reached the highest level in YPD40 medium ( Fig. 8A However, astaxanthin production decreased with increasing initial glucose concentration ( Fig. 8AIn addition, a clear positive correlation was observed between the initial glucose content and the accumulation of intermediates, including β-carotene and ketocarotenoid intermediates ( Fig.14 ). This may be attributed to the increased lipid content resulting from the higher C / N ratio, which in turn resulted in more β-carotene being sequestered in lipid bodies (Larroude et al., 2018), where the LB-targeted enzyme was shown to be limiting, leading to intermediate accumulation. Based on these results, YPD20 medium was chosen to demonstrate astaxanthin production in fed-batch fermentation. Strain YL17 achieved total astaxanthin titers and contents of 858 mg / L and 16.7 mg / g DCW, respectively, in flask fed-batch fermentation ( Figure 8B ), which is the highest reported so far among yeasts. In addition, the performance of the constructed strain was evaluated by scaling up the fermentation to a 3-L bioreactor. However, only an astaxanthin titer of 453 mg / L was obtained ( Figure 8C ), indicating that further optimization of fermentation in fermenters is needed in the future.

[0153] Simultaneous anchoring of the enzyme to all three organelles produced the greatest increase in astaxanthin synthesis, and ultimately produced 858 mg / L of astaxanthin in a fed-batch fermentation (a 141-fold increase over the initial strain). The methods and products disclosed herein are expected to help unlock the full potential of subcellular compartments and promote LB-based compartmentalized isoprenoid biosynthesis in Yarrowia lipolytica.

[0154] As described above, the present disclosure relates to the fusion expression of two key enzymes in the astaxanthin pathway and the performance of the fusion when the fusion is targeted to various subcellular compartments. The activities of the key enzymes β-carotene ketolase (CrtW) and hydroxylase (CrtZ) from different sources were evaluated, and it was found that PsCrtW / HpCrtZ (derived from Paracoccus and Haematococcus pluvialis, respectively) were the best for astaxanthin accumulation. The activities of PsCrtW and HpCrtZ were combined by creating an enzyme fusion to overcome the leakage of non-endogenous intermediates. Finally, the astaxanthin biosynthetic pathway of the above-mentioned fusion enzymes was targeted to the subcellular compartments of lipid bodies (LBs), alone or in combination with compartmentalization of the endoplasmic reticulum (ER) and peroxisomes. Relative to the cytosolic pathway, directing the astaxanthin pathway to organelles produced a significant increase in yield and a reduction in intermediate accumulation. Furthermore, simultaneously targeting the astaxanthin pathway to all three LBs, ER, and peroxisomes produced the highest yield of astaxanthin and ultimately reached 858 mg / L (16.7 mg / g DCW) in fed-batch fermentation. These results demonstrate the potential of Yarrowia lipolytica for lipophilic metabolite production by targeting pathway expression to subcellular compartments that allow the biosynthetic pathway to operate efficiently.

[0155] These strategies described herein are used to maximize the production of the carotenoid astaxanthin in Yarrowia lipolytica. First, a functional fusion of β-carotene ketolase and hydroxylase (CrtW-Z or CrtZ-W) was created, and the astaxanthin production was increased relative to the level reached by the enzyme (CrtW+Z) expressed individually in Yarrowia lipolytica. In terms of intermediate accumulation, the biggest difference between the enzyme expressed individually and the fusion enzyme is the characteristics of canthaxanthin and zeaxanthin in the CrtW+Z strain, and the characteristics of 3'-hydroxy-echinone in the CrtW-Z strain. Canthaxanthin or zeaxanthin are synthesized by β-carotene in two enzymatic steps, requiring only CrtW or CrtZ, respectively, while the production of 3'-hydroxy-echinone requires the participation of two enzymes. This quantitative change in the composition of the intermediates between CrtW+Z and CrtW-Z strains can show that when the two enzymes are fused, canthaxanthin and zeaxanthin are more easily converted into downstream metabolites. The reduction of intermediate leakage and the acceleration of the overall reaction rate highlight the enhancement of enzyme interactions when fused together.

[0156] Example 4. Materials and methods related to Example 3

[0157] Culture conditions and media

[0158] Escherichia coli DH5α cells were grown in Luria-Bertani (LB) medium (BD bioscience) at 37°C, with continuous shaking. The corresponding antibiotics (100 μg / mL ampicillin and 50 μg / mL kanamycin) were added for plasmid selection. All Yarrowia lipolytica strains were cultured at 30°C and 230rpm with shaking. For Yarrowia lipolytica, the YPD medium consisting of 10g / L yeast extract (BD bioscience), 20g / L peptone (BD bioscience) and 20g / L glucose (Sigma-Aldrich) was used. In addition, YNB medium included 1.7g / L yeast nitrogen base (yeast nitrogenbase) (YNB, VWR Life Science), 20g / L glucose, 5g / L ammonium sulfate, 15g / L agar (BD bioscience) and 0.77g / L appropriate complete supplement mixture (without uracil, leucine or tryptophan) (Sunrise science products) for selecting the Yarrowia lipolytica strain transformed.

[0159] Plasmid and strain construction

[0160] Escherichia coli DH5α was used for cloning and plasmid propagation. The Yarrowia lipolytica po1f strain was used as the base strain, and all derivatives and plasmids constructed are listed in Table 2. The primers used for plasmid construction are listed in Table 3. All restriction enzymes were purchased from New England Biolabs (NEB). PCR amplification was performed using Q5 high-fidelity DNA polymerase (NEB) or GoTaq DNA polymerase (Promega). PCR fragments were purified using the ZYMO Fragment Recovery Kit (ZYMO research). Plasmids were then constructed from the purified PCR fragments using the Gibson Assembly Kit (NEB), transformed into chemically competent Escherichia coli cells by heat shock, and extracted using the QIAprep Spin Miniprep Kit (Qiagen). All procedures were performed according to the manufacturer's instructions. All engineered Yarrowia lipolytica strains were constructed by transforming linearized plasmids (Not1 digested) using the lithium acetate method. Recombinants were verified by PCR amplification of genomic DNA. The astaxanthin biosynthetic genes evaluated in this study were all codon-optimized for Yarrowia lipolytica.

[0161] Auxotrophic marker management via the Cre-loxP system

[0162] Plasmid pYLMA-Cre is transformed into the target Yarrowia lipolytica strain to rescue URA3, LEU2 and TRP1 markers. Transformants are selected on YPD agar plates supplemented with a final concentration of 250 mg / L hygromycin B (Sigma-Aldrich). After 2-3 days of cultivation, the colonies are transferred to a new YPD plate containing hygromycin B for another day to allow for more successful deletion of markers. Marker management is confirmed by subculturing the colonies onto YNB-Ura, YNB-Leu and YNB-Trp agar plates, respectively. Successful removal of all three markers results in a phenotype that confer uracil, leucine and tryptophan deficiency. The plasmid pYLMA-Cre in the cells is then removed by incubating the positive strains on YPD agar plates at 30°C for 24 hours (2-3 replicates).

[0163] Shake flask fermentation

[0164] A single colony of the recombinant strain was picked from the plate, inoculated into 2 mL of YPD medium, and cultured overnight (16-18 hours) at 30°C and 230 rpm. The culture medium was then transferred to 10 mL of YPD medium (initial OD 600 =0.1) in a 50 mL shake flask and cultured at 30°C and 230 rpm for 3 days.

[0165] Quantification of residual glucose in the culture medium

[0166] 500 μL samples were extracted from the culture for residual glucose quantification. The cells were centrifuged at 12,000 rpm for 5 minutes, and the supernatant was then filtered through a 0.2 μm injector filter and then injected into an Agilent technologies 1260 high performance liquid chromatograph (HPLC) equipped with a refractive index detector. Separation was performed using a Bio-Rad HPX-87H column with 14 mM sulfuric acid as the mobile phase at a flow rate of 0.7 mL / min. The injection volume was 10 μL. The column temperature was 50 ° C.

[0167] Carotenoid extraction

[0168] Carotenoid extraction was performed as described (Asker, 2017) with the following modifications. Briefly, 50-100 μL of culture was centrifuged at 12,000 g for 1 min, and the cell pellet was suspended in 900 μL of dimethyl sulfoxide (DMSO) and then heated at 50 °C for 1 h until the cells were bleached in a water bath. The DMSO extract was briefly mixed with 450 μL of methanol and centrifuged at 14,000 g for 5 min. The resulting supernatant was transferred to a glass vial for carotenoid analysis and quantification.

[0169] Analysis and Quantification of Carotenoids

[0170] Carotenoid production was expressed as grams per liter of fermentation broth (g / L) and milligrams per gram of dry cell weight (mg / gDCW). The optical density at 600 nm was measured using a Thermo Spectronic Genesys 20 (Thermo Scientific) and used to calculate cell mass (DCW = 0.30 × OD 600 , Fig.15 ). Analysis and quantification of astaxanthin were performed by HPLC (SHIMADZU LC-20AT) equipped with a Kromasil C18 column (4.6 mm x 250 mm) and UV / VIS detection at 475 nm. The mobile phase consisted of acetonitrile-methanol-isopropanol (5:3:2 v / v) at a flow rate of 1 mL / min and a temperature of 40°C. A standard curve of astaxanthin (Sigma-Aldrich) was prepared by running the same extraction process as the samples.

[0171] Targeting biosynthetic pathways to subcellular compartments

[0172] The fusion enzyme CrtW-Z dependent astaxanthin biosynthetic pathway was targeted to different subcellular compartments (ER, LB and peroxisome) using specific addressing signals. Enzymes involved in the astaxanthin biosynthetic pathway were directed to the ER by adding a C-terminal KDEL using the following nucleotide sequence 5'-AAGGACGAGCTG-3' (SEQ ID NO:6) while removing the stop codon at the end of the targeting signal. Protein homology, peroxisome or LB targeting was ensured by adding SKL (nucleotide sequence 5'-TCCAAGCTG-3') or oleosin from corn (codon-optimized oleosin sequences are listed in Table 4) as previously done in other works on engineering Yarrowia lipolytica (Yang et al., 2019). The fusion enzyme CrtW-Z without any targeting signal was directed to the cytoplasm.

[0173] Fed-batch fermentation

[0174] Bioreactor fed batch fermentation was carried out in a 3L fermentor (New Brunswick Bioflo115 system). Initial fermentation was carried out in 1L of medium containing 100g / L glucose, 100g / L peptone and 50g / L yeast extract. The temperature was maintained at 30°C. Dissolved oxygen was controlled at 20% saturation, with a stirring cascade of 250-800rpm. Air was sprayed into the fermentor at 2vvm. The pH was maintained at 6.8 by feeding 5M NaOH or 5M HCL. Foam was prevented by adding defoamer 204 (Sigma-Aldrich). Fed batch operation was started after culturing for 72 hours with 15x YPD medium. Sampling was performed every 24 hours to measure OD 600 , glucose and astaxanthin concentrations. Flask fed-batch fermentations were performed in 50 mL conical flasks with a working volume of 10 mL YPD medium. 15x YPD medium was fed every 48 hours and pH was not controlled.

[0175] Table 1. List of β-carotene ketolases and hydroxylases used in Example 3.

[0176]

[0177] Table 2. Strains and constructs used in Example 3.

[0178]

[0179] Table 3. Primers used in Example 3.

[0180]

[0181]

[0182] Table 4. Codon-optimized sequences of oleosins used in Example 3.

[0183]

[0184]

[0185] Table 5. Concentrations of carotenoids involved in the astaxanthin pathway.

[0186]

[0187] *Due to the lack of standard compounds, these intermediates were calculated as astaxanthin equivalents.

[0188] Example 5. Removal of lycopene substrate inhibition results in high carotenoid productivity in Yarrowia lipolytica

[0189] Substrate inhibition of enzymes can be a major obstacle to the production of valuable chemicals by engineering microorganisms. Substrate inhibition of lycopene cyclase has been identified as a major limitation in carotenoid biosynthesis in Yarrowia lipolytica. To overcome this bottleneck, two independent approaches were used. Structure-guided protein engineering produced variant Y27R, characterized by complete loss of substrate inhibition without reducing enzyme activity. Alternatively, the establishment of a flux limiter mediated by geranylgeranyl pyrophosphate synthase also prevents the occurrence of substrate inhibition by diverting metabolic flux from inhibitory metabolites while maintaining sufficient flux to product formation. Both methods are very effective, resulting in high levels of almost exclusive β-carotene production. A strain capable of producing 39.5 g / L β-carotene with a productivity of 0.165 g / L / h in bioreactor fermentation was eventually constructed (1441 times higher than the initial strain). The discovery described herein provides an effective way to remove substrate inhibition in engineered pathways for the efficient synthesis of natural products.

[0190] Engineering microorganisms to produce valuable chemical products is an attractive alternative to obtaining these compounds from nature or from petrochemicals through chemical synthesis (Chen and Nielsen., 2013; Li and Smolke, 2016; Liu and Nielsen, 2019). However, synthetic biology efforts to achieve economically viable and scalable titers and productivity are often hindered by undesirable regulatory mechanisms that regulate enzyme activity. Such mechanisms have evolved to mediate optimal cellular responses to changing physiological conditions, but also represent a major obstacle to diverting metabolic flux to desired engineered metabolic pathways and away from natural growth-optimized pathways. This problem is particularly evident in compounds that require long and complex synthetic pathways (such as isoprenoids), often leading to bottlenecks that reduce cell fitness and pathway productivity (Wu et al., 2016; Keasling et al., 2010). Therefore, it is necessary to develop methods that allow us to bypass the effects of enzyme inhibition in building robust strains with high productivity.

[0191] Substrate inhibition represents an enzyme level regulation deployed in cells that helps optimize the cellular economy and maximize growth in response to temporal changes in the environment (Reed et al., 2010). In addition, this mechanism is often used to design treatments for various diseases (Boutin et al., 2005; Belzer et al., 2013). However, this is undesirable in industrial applications of microorganisms for product synthesis mediated by enzymatic reactions. Enzyme inhibition is usually triggered when the substrate concentration exceeds a certain threshold, thereby preventing the catalytic conversion of the substrate and limiting the flux through the desired pathway. Therefore, when substrate inhibition is present in the middle of a metabolic pathway, it is particularly detrimental to the synthesis of the end product of interest, which in turn leads to accumulation of intermediates, interruption of the pathway, and changes in the characteristics of the formed products. Although various approaches have been explored to address this limitation, such as enzyme immobilization (Singh et al., 2013; Matwo et al., 2004), two-phase partition bioreactor systems (Daugulis et al., 2011; Gao et al., 2009; Nielsen et al., 2009), batch substrate feeding strategies (Kim et al., 2007), and protein engineering (Chen et al., 2014; Shang et al., 2020), most of these solutions are limited to systems where inhibition is caused by the starting substrate and are difficult to apply in the context of chemical production microbial engineering.

[0192] Two independent strategies for almost completely bypassing substrate inhibition were demonstrated using the oleaginous yeast Yarrowia lipolytica for carotenoid overproduction. First, lycopene cyclase was identified as a bottleneck for carotenoid synthesis due to its strong inhibition by lycopene. This not only results in low titers of β-carotene, but also in large amounts of accompanying lycopene as a byproduct. In view of this, the first strategy was to use structure-guided protein design, combined with phylogenetic information, to generate protein variants with reduced inhibition. Among the 50 variants generated, a single mutation, Y27R, was identified that completely eliminated substrate inhibition without reducing enzyme activity, resulting in a significant increase in β-carotene production, and a selectivity of 98% (% of the product in the sum of all carotenoids). Alternatively, in the second approach, similar titers and selectivities of β-carotene were obtained by reducing carbon flux through the carotenoid pathway and thus preventing inhibitory metabolites from accumulating to inhibitory levels, which is contrary to the traditional pathway engineering paradigm. This was achieved by establishing a geranylgeranyl pyrophosphate synthase (GGPPS)-mediated metabolic flux limiter that regulates the rate of substrate lycopene formation, effectively alleviating substrate inhibition. Although this approach reduces flux through the pathway of interest, the benefits of suppressing substrate levels and thus maintaining high enzyme activity overcompensate for any productivity loss caused by the flux diversion. Using the methods outlined above, and carefully dividing cellular resources dedicated to carotenoid synthesis and storage, a strain was ultimately established that was able to produce 39.5 g / L β-carotene (98% selectivity) at a volumetric productivity of 0.165 g / L / h in bioreactor fermentation. In addition, by deliberately exploiting the substrate inhibition effect and instead shifting the product profile towards lycopene, a lycopene titer of 17.6 g / L and a productivity of 0.073 g / L / h were achieved.

[0193] Substrate inhibition of lycopene cyclase limits carotenoid synthesis

[0194] The synthesis of β-carotene in Yarrowia lipolytica requires heterologous expression of three genes encoding the enzymes phytoene synthase, phytoene dehydrogenase, and lycopene cyclase ( Fig.16A and Fig. 22 In addition, geranylgeranyl diphosphate synthase (GGPPS) should also be considered, as it controls the flux towards carotenoid rather than sterol synthesis ( Fig.16A and Fig. 22). The relevant genes were derived from the eukaryotic organisms Phaffia and Mucor circinelloides for expression. Since Yarrowia lipolytica already contains a natural copy of GGPPS, the first step was to introduce gene expression cassettes encoding phytoene dehydrogenase and bifunctional phytoene synthase / lycopene cyclase from Phaffia (CrtI and CrtYB, respectively) (Verdoes et al., 1999; Verdoes, Krubasik et al., 1999) or Mucor circinelloides (CarB and CarRP, respectively) (Velayoes, Blasco et al., 2000; Velayos, Eslava et al., 2000) into the Yarrowia lipolytica po1f strain with a disruption of TRP1 (po1f-T) ( Fig.23 and Table 6). Strain YLMA02 (which expressed the enzyme from Mucor circinelloides) produced 4.12 times more β-carotene (27.4 mg / L) than strain YLMA01 (which expressed the enzyme from Phaffia spp.) Fig. 16B ). Therefore, the CarB / CarRP pair was used in all further studies.

[0195] Although β-carotene synthesis was observed in YLMA02, the titer was very low, which prompted us to investigate the GGPPS step as the next target. Introduction of an additional copy of GGPPS from Phaffia yeast (GGPPxd) into strain YLMA02 significantly increased the titer of β-carotene to 0.48 g / L ( Fig. 16C ). However, this was also accompanied by a substantial increase in lycopene accumulation ( Fig. 16C ), suggesting that the cyclization of lycopene to β-carotene is the pathway bottleneck. Accordingly, by increasing its gene copy number, the expression of lycopene cyclase also increased. In addition, since cyclase activity is conferred by the R domain of the bifunctional enzyme CarRP (Velayos, Eslava et al., 2000), a modified version of this protein in which the P domain was deleted or mutated was also introduced ( Fig.24A ), making it act as a dedicated cyclase. Although higher mRNA levels were observed ( Fig.24C ), but these efforts have not been successful in improving β-carotene titers ( Fig. 24B Next, the effect of introducing lycopene cyclases from four other organisms (EuCrtY, PaCrtY, PfCrtY, and HpCrtY) was examined (Table 6), which resulted in modest improvements in β-carotene production ( Fig.24D ). However, the issue of lycopene accumulation remains largely unresolved, suggesting that overexpression of lycopene cyclase is not an effective strategy regardless of its source. The protein level of lycopene cyclase is most likely not a limitation of this study.

[0196] Since lycopene is the only aggregation precursor ( Fig.25 ), and adding additional copies of various lycopene cyclases did not circumvent this problem, so it was assumed that the activity of lycopene cyclases was inhibited by excess lycopene through substrate inhibition ( Fig.16A To test this hypothesis, an in vitro enzymatic assay using a yeast microsomal system was used to examine the possible correlation between lycopene cyclase activity and lycopene concentration, since CarRP is predicted to be a membrane protein with six transmembrane helices ( Fig.26 ). The results showed that lycopene cyclase activity had a biphasic relationship with lycopene concentration: the enzyme activity initially increased with increasing lycopene concentration and then decreased when lycopene reached higher concentrations ( Fig.16D ). This supports the hypothesis that lycopene cyclase is inhibited by its substrate, thus creating a major bottleneck in carotenoid biosynthesis.

[0197] Structure-guided protein engineering completely removes substrate inhibition

[0198] We next evaluated the removal of substrate inhibition of lycopene cyclase by protein engineering. Since its crystal structure was not available, a computational model of the R domain of CarRP (lycopene cyclase) was created using the Transformation Constraint Rosetta (TrRosetta) platform (Yang et al., 2020) Fig. 27 ). Evolutionary information was used to identify mutable positions by generating a position-specific scoring matrix (PSSM) from a multiple sequence alignment to deconvolute enzyme regions that affect substrate inhibition. Single and double amino acid substitutions were created based on the PSSM information and clustered to ensure maximum spread of the tested variants ( Fig.28 ). The variants were clustered using PAM30 to calculate distances between sequences, and agglomerative hierarchical clustering was used to subdivide the sequences, maximizing the information obtained during the initial screening. By this approach, a set of 50 candidates was generated in which the mutations were spread throughout the enzyme ( Fig.17A The selectivity of each variant for β-carotene was obtained ( Fig. 17B Among them, three variants, Y27R, V175W and T31R-F92W, showed significantly increased β-carotene selectivity and improved production indicators ( Figures 17B-17C ) without affecting gene expression ( Fig.29 ), indicating a reduction in substrate inhibition. The substitutions in all three variants are located in specific parts of the enzyme ( Fig.30 ), with Y27R showing the most pronounced loss of inhibition. Variant Y27R demonstrated complete loss of substrate inhibition without loss of enzyme activity ( Fig.16D ), and produced a β-carotene titer of 2.38 g / L ( Fig. 17C), together with 98% selectivity (compared to 18% for wild type, Fig.17D ).

[0199] We then investigated whether the β-carotene pathway containing the variant Y27R could maintain its property of minimal substrate inhibition despite a significantly higher precursor / substrate formation ratio. To this end, we used the Y27R-expressing β-carotene producing strain YLMA11 ( Fig.17E ) overexpressed four key enzymes of the mevalonate (MVA) pathway, tHMGR, ERG12, IDI, and ERG20 (Ro et al., 2006; Westfall et al., 2012) ( Fig. 22 ). This resulted in an increased titer of β-carotene of 3.43 g / L while maintaining a high selectivity of 97.8%. In addition, a synthetic isopentenol utilization pathway (IUP) was introduced by expressing choline kinase (CK) and isopentenyl phosphate kinase (IPK) (Chatzivasileiou et al., 2019; Clomburg et al., 2019; Rico et al., 2019; Lund et al., 2019)( Fig. 22 ), resulting in an additional 23% increase in β-carotene production (4.22 g / L) without any loss in selectivity (YLMA15, Fig.17E ). These results indicate that the reconstructed non-substrate inhibition pathway functions efficiently in the high isoprenoid flux strain and is not affected by the intracellular levels of precursors / substrates in the cells.

[0200] Managing substrate inhibition of lycopene cyclase via a GGPPS-mediated flux limiter

[0201] Other possible options that could eliminate substrate inhibition without modifying lycopene cyclase were also explored. It was hypothesized that attenuating the formation rate of lycopene relative to its conversion rate could potentially reduce the intracellular concentration of lycopene below the inhibitory level. However, this would need to be fine-tuned to prevent an overall reduction in the production rate of the end product due to attenuating the lycopene formation rate too much. To this end, branch points at FPP nodes were used to create metabolic flux limiters and adjust the flux towards lycopene, for example to maintain sub-inhibitory levels, and also high lycopene conversion to β-carotene ( Fig.18A Therefore, five different enzymes (Table 6) were screened to search for GGPPS mutants with variable activities, with their different catalytic efficiencies measured by their in vivo GGPP synthesis rates ( Fig.18B ). Relative to GGPPxd, the other four GGPPS showed lower productivity ( Fig.18B), which should translate into a lower lycopene synthesis flux. When GGPPsa from S. acidocaldarius was used, the lycopene levels were reduced after introducing these less active GGPPS into strain YLMA02 (the base strain containing wild-type CarRP) ( Fig.18C ), and the β-carotene production increased to 1.26 g / L with a selectivity of 92.5% ( Fig.18C This was further confirmed by the time course of lycopene and β-carotene concentrations ( Fig.18D Interestingly, although expression of attenuated GGPPsa (YLMA25) slightly reduced the flux devoted to carotenoid synthesis, it bypassed any substrate inhibition and achieved an overall balanced pathway that directed all carbon flux toward β-carotene formation, allowing the pathway to behave similarly to the variant with Y27R (YLMA11, Fig.18D In contrast, strain YLMA03, which expresses a very efficient GGPPxd, caused lycopene to accumulate at an excessively rapid rate, triggering substrate inhibition and preventing its conversion to β-carotene ( Fig.18D ). These results suggest that the GGPPS-mediated metabolic flux limiter can effectively relieve substrate inhibition to regulate the flux both upstream and downstream of lycopene for optimal conversion to β-carotene.

[0202] To bridge the gap in β-carotene production between two engineering strategies to alleviate substrate inhibition ( Fig. 17C and Fig.18C ), by inserting additional copies to overexpress the GGPPS-mediated flux restrictor-supported pathway ( Fig.18E ). This regulation not only enhanced β-carotene biosynthesis to 2.13 g / L, but also further maximized its selectivity (from 92.1% to 98.1%, Fig.18E ). In addition, similar to previous results, overexpression of MVA and IUP promoted the production of β-carotene to 3.72 g / L without affecting the selectivity ( Fig.18F ). This further emphasizes the fact that the pathway can operate efficiently once substrate inhibition is resolved.

[0203] By changing the activity of GGPPS in vivo, the product characteristics of β-carotene and lycopene can be changed ( Figures 18B-18C ). The high activity of GGPPxd can also be used to reconstruct a specialized lycopene-producing strain. This idea was combined with the CarRP variant (E78K) (Velayos, Eslava et al., 2000) ( Figures 32A-32B ), successfully produced 2.62g / L of lycopene, of which the amount of β-carotene was undetectable ( Figure 18GBy overexpressing the MVA pathway and introducing IUP, lycopene production was further increased, reaching a titer of 3.09 g / L (YLMA34, Fig.33 ).

[0204] Partitioning carbon flux between isoprenoid and lipid synthesis to enhance intracellular carotenoid accumulation

[0205] Liposomes in Yarrowia lipolytica create hydrophobic pockets that facilitate sequestration and storage of lipophilic isoprenoid products (Qiao et al., 2017). However, while increasing triacylglycerol (TAG) supply enhances isoprenoid storage (Ma et al., 2019; Larroude et al., 2018), this is at the expense of acetyl-CoA, a common precursor for isoprenoid and lipid synthesis ( Fig.19A ). Therefore, carbon flux needs to be optimally divided between lipid and isoprenoid synthesis, with the goal of ensuring an adequate lipid supply to encapsulate the produced isoprenoids while not drawing too much acetyl-CoA away from the MVA pathway. To this end, we set out to cultivate the β-carotene-producing strain YLMA15 ( Fig.34 ), because the ability of lipid formation can be easily controlled by the C / N ratio of the culture medium (Braunwald et al., 2013; Somashekar et al., 20000). The initial glucose concentration in all conditions was fixed at 50 g / L, which was determined to be optimal for the strain ( Fig.35 ). It was found that as the C / N ratio increased, the lipid content of the cells increased monotonically ( Fig.19B ), while total biomass decreases (due to reduced nitrogen availability, Fig.36 ). However, using Y 10 P 10 D 50 (10 g / L yeast extract, 10 g / L peptone and 50 g / L glucose) medium (C / N ratio of 9:1) to obtain a titer (7.5 g / L, Fig.19C ) and cell content (360.8 mg / g DCW, Fig.19D ) for β-carotene production. Deviation from this optimal condition resulted in decreased β-carotene levels, which is consistent with the hypothesis and emphasizes the importance of an optimal balance between carotenoid and lipid biosynthesis. 10 P 10 D 50 The medium was also suitable for a lycopene-producing strain (YLMA34), where a lycopene concentration of 8.02 g / L was obtained after 5 days of fermentation ( Fig.37 ).

[0206] Cellular lipid degradation supports carotenoid biosynthesis during the steady state of glucose depletion

[0207] In the fermentation experiments described herein with strain YLMA15, it was found that the β-carotene content continued to rise during the stationary phase, even after the glucose in the culture medium had been depleted ( Fig. 20A lipolytica likely mobilized previously stored TAG as an alternative carbon source to support carotenoid formation (Wang et al., 2020). To test this hypothesis, we set out to characterize the cells along with their intracellular lipids before and after glucose depletion. Throughout the fermentation, lipid content initially increased, reaching a maximum on day 3, and then rapidly declined when glucose was completely consumed ( Fig. 20A ). However, despite the decrease in lipid content, β-carotene content continued to rise well beyond the point of glucose depletion ( Fig. 20A ), suggesting that TAG is used to maintain metabolic activity and carotenoid synthesis. Microscopic visualization of the changes that occurred during the fermentation process is consistent with this hypothesis. During the first 3 days, when glucose was still present, intracellular lipid droplets gradually aggregated into lipid bodies, thereby sequestering the produced β-carotene ( Fig.38 However, it was apparent that lipid bodies were no longer visible late in the fermentation due to TAG breakdown, which in turn caused the accumulated β-carotene to become more dispersed throughout the cell ( Fig.38 ).

[0208] Since TAG degradation is mainly through β-oxidation to generate acetyl-CoA (Xu et al., 2016) ( Fig.19A ), so it is likely that this provides the carbon skeleton for β-carotene synthesis during the glucose depletion stabilization period. To test this hypothesis, in the presence of uniformly labeled [U- 13 YLMA15 was cultured in YNB medium containing C6] glucose and naturally abundant stearic acid. After the addition of stearic acid, which is metabolized by β-oxidation, most of the unlabeled IPP / DMAPP and GGPP (the main precursor for β-carotene synthesis) were observed within 24 hours of culture ( Figures 20B-20C ). These results suggest that acetyl-CoA formed via β-oxidation can indeed support the MVA pathway and ultimately contribute to β-carotene formation. Therefore, this may be the mechanism used by cells to convert TAG to carotenoids during the steady state of glucose depletion.

[0209] Bioreactor culture studies

[0210] Finally, the performance of the constructed strain with reduced substrate inhibition in a 3-L fed-batch culture was evaluated. After bioreactor optimization, strain YLMA15 achieved a total β-carotene titer and content of 39.5 g / L and 494 mg / g DCW, respectively, with a productivity of 0.165 g / L / h ( Figures 21A-21CSimilarly, bioreactor fermentation of lycopene-producing strain YLMA34 produced 17.6 g / L lycopene (313 mg / g DCW), with a productivity of 0.073 g / L / h ( Figures 21D-21F ). Notably, no change in the selectivity for β-carotene in strain YLMA15 was observed during scale-up (98% in the fed-batch bioreactor compared to 97.9% in the shake flask ( Fig.39 )). These figures demonstrate the robustness of the engineering strategy in large culture volumes and high cell density fermentations, where production metrics exceed previous results (a summary of reported carotenoid production is provided in Table 8).

[0211] The present disclosure relates to the demonstration that lycopene cyclase impairs β-carotene production through substrate inhibition, a regulatory effect that has been less reported in the context of microbial synthesis. Substrate inhibition of enzymes can be overcome by modifying protein structure (a strategy that has been successfully applied to many enzymes) (Shang et al., 2020). However, these efforts rely on readily available protein crystal structures, which is not the case for the lycopene cyclase studied herein. Although directed evolution is a powerful approach to adapt enzymes to specific tasks (Reetz et al., 2013), it generally requires high-throughput assays to screen large libraries. In addition, due to the lack of crystal structure information, effective structure-driven design relies heavily on both the quality of computational modeling and the accuracy of docking substrates to their binding sites. This paper combines structural and phylogenetic information, which improves the search and allows us to isolate promising mutants by screening only 50 variants, of which 3 variants show reduced or removed substrate inhibition. In addition, information on key amino acids can be iteratively fed back into the computational model to further optimize enzyme properties. A more thorough study is required to mechanistically understand what factors cause substrate inhibition removal, which is beyond the scope of this study. The small number of designed and tested protein variants suggests that structure-guided approaches combined with phylogenetic information provide an effective strategy for protein engineering.

[0212] The extent of substrate inhibition can also be controlled by regulating the relative rates of upstream and downstream pathways that form and consume inhibitory substrates. In the case of β-carotene synthesis, selecting a GGPPS variant with lower activity reduces the flux through the carotenoid pathway. However, the resulting elimination of substrate inhibition diverts all carotenoid flux to β-carotene synthesis, unlike the combination of lycopene and β-carotene. Despite the lower GGPPS activity, this results in an increase in β-carotene production with high specificity (>98%). On the other hand, if lycopene is the desired product, substrate inhibition can also be used intentionally. In this case, efficient GGPPS can cause lycopene formation to exceed its consumption, leading to its accumulation, and then further amplifying the imbalance through substrate inhibition. Accordingly, the product characteristics are sharply transformed from being rich in β-carotene to being rich in lycopene. These findings show that engineering proximal enzymes can have a profound impact on pathway dynamics, providing a new paradigm for controlling metabolism.

[0213] Another important consideration in metabolic engineering is how heterologous pathways interact with native pathways. Designing pathways that are orthogonal to or have minimal impact on the native functions of an organism has been the focus of many strain engineering efforts (Ro et al., 2006; Tan et al., 2016; Zhao et al., 2018; Brockman et al., 2015). It is well known that the lipophilic nature of carotenoids promotes their storage in cellular lipid bodies. Larroude et al. (Larroude et al., 2018) found that engineered lipid overproduction strains were able to produce more β-carotene, with a titer of 6.5 g / L accompanied by the production of 42.6 g / L lipid. While providing a compatible compartment for the accumulation of hydrophobic isoprenoids, the de novo formation of TAGs also consumes a large amount of carbon source, resulting in limited acetyl-CoA flux to the MVA and product formation pathways. Here, it is demonstrated that the native TAG accumulation capacity of Yarrowia lipolytica is sufficient for carotenoid sequestration. By balancing the flux distribution between carotenoid and lipid synthesis through C / N ratio adjustment, a larger portion of the acetyl-CoA pool is retained for carotenoid production, thereby achieving higher titers and content per cell.

[0214] Example 6. Materials and methods related to Example 5

[0215] Culture conditions and media

[0216] Escherichia coli DH5α cells were cultured at 37°C in Luria-Bertani (LB) medium (BD bioscience) with continuous shaking. The corresponding antibiotics (100 μg / mL ampicillin and 50 μg / mL kanamycin) were added for plasmid screening. All Yarrowia lipolytica strains were cultured at 30°C and shaken at 230rpm. For Yarrowia lipolytica, the YPD medium consisting of 10g / L yeast extract (BD bioscience), 20g / L peptone (BD bioscience) and 20g / L glucose (Sigma-Aldrich) was used. In addition, the YNB medium including 1.7g / L yeast nitrogen base (YNB, VWR LifeScience), 20g / L glucose, 5g / L ammonium sulfate (VWR Life Science), 15g / L agar (BD bioscience) and 0.77g / L appropriate complete supplement mixture (without uracil, leucine or tryptophan) (Sunrise scienceproducts) was used to select the transformed Yarrowia lipolytica strain.

[0217] Plasmid and strain construction

[0218] Escherichia coli DH5α was used for cloning and plasmid propagation. The Yarrowia lipolytica po1f strain was used as the base strain, and all derivatives and plasmids constructed in this study are listed in Table 7. The primers used for plasmid construction are shown in Table 9. All restriction enzymes were purchased from New England Biolabs (NEB). PCR amplification was performed using Q5 high-fidelity DNA polymerase (NEB) or GoTaq DNA polymerase (Promega). PCR fragments were purified using the ZYMO fragment recovery kit (ZYMO research). Plasmids were then constructed from the purified PCR fragments using the Gibson assembly kit (NEB), transformed into chemically competent Escherichia coli cells by heat shock, and extracted using the QIAprep Spin Miniprep kit (Qiagen). All procedures were performed according to the manufacturer's instructions. All engineered Yarrowia lipolytica strains were constructed using the lithium acetate method to transform linearized plasmids (Not1 digestion). Recombinants were verified by PCR amplification of genomic DNA. The carotenoid biosynthesis genes evaluated in this study were codon-optimized for Yarrowia lipolytica.

[0219] Disruption of TRP1 in the po1f strain using CRISPR-Cas9

[0220] For TRP1 disruption, a CRISPR-Cas9 plasmid (Schwartz et al., 2016) containing a gRNA (ACGCCGAGGAGTGGTACCGG) (SEQ ID NO: 30) targeting the TRP1 (YALI0B07667g) gene of Yarrowia lipolytica was transformed into the strain po1f with Ura3 as an auxotrophic marker. Strains with tryptophan auxotrophy were obtained by screening on YNB-Ura and YNB-Ura-Trp plates. Thereafter, positive clones were inoculated on YPD plates and subcultured three times to lose the CRISPR-Cas9 plasmid, obtaining the po1f-T strain (ura3 - leu2 - , trp1 - ).

[0221] Auxotrophic marker management via the Cre-loxP system

[0222] Plasmid pYLMA-Cre was transformed into the target Yarrowia lipolytica strain to rescue the URA3, LEU2 and TRP1 markers. Transformants were selected on YPD agar plates supplemented with a final concentration of 250 mg / L hygromycin B (Sigma-Aldrich). After 2-3 days of culture, the colonies were transferred to new YPD plates containing hygromycin B for another day to allow for more successful marker deletion. Marker management was confirmed by subculturing the colonies onto YNB-Ura, YNB-Leu and YNB-Trp agar plates, respectively. Successful removal of all three markers will result in a phenotype that conferred uracil, leucine and tryptophan deficiency. The plasmid pYLMA-Cre in the cells was then removed by incubating the positive strains on YPD agar plates at 30°C for 24 hours, repeated 2-3 times.

[0223] Shake flask fermentation

[0224] A single colony of the recombinant strain was picked from the plate, inoculated into 2 mL of YPD medium, and cultured overnight (16-18 h) at 30°C and 230 rpm. The culture was then transferred to a plate containing 10 mL of YPD medium (initial OD 600 =0.1) in a 50 mL shake flask and cultured with shaking at 30°C and 230 rpm for 3-5 days. Where appropriate, when the glucose of the culture was almost exhausted, 30 mM prenol (Sigma-Aldrich) was added to the YPD medium.

[0225] Bioreactor fermentation

[0226] Fed-batch fermentation was carried out in a 3L bioreactor (New Brunswick Bioflo115 system). Initial fermentation was completed in 1L medium containing 100g / L glucose, 100g / L peptone and 50g / L yeast extract. The temperature was maintained at 30°C. The dissolved oxygen was controlled at 20%, with a stirring cascade of 250-800rpm. Air was sparged into the fermenter at 2vvm. The pH was maintained at 6.8 by feeding 5M NaOH or 5M HCL. Foaming was prevented by adding defoamer 204 (Sigma-Aldrich). In 10xY 10 P 10 D 50 The fed-batch process was started after 48 hours of cultivation in medium (consisting of 100 g / L yeast extract, 100 g / L peptone and 500 g / L glucose). Once the medium feed was started, stirring and aeration were changed and kept constant at 600 rpm and 0.3 vvm, respectively. Samples were taken every 24 hours to measure OD 600 , glucose concentration, and carotenoid titer.

[0227] Quantification of residual glucose in the culture medium

[0228] 500 μL samples were extracted from the culture for residual glucose quantification. The cells were centrifuged at 12,000 rpm for 5 min, and the supernatant was then filtered through a 0.2 μm injector filter and then injected into an Agilenttechnologies 1260 high performance liquid chromatograph (HPLC) equipped with a refractive index detector. A Bio-Rad HPX-87H column was used for separation, with 14 mM sulfuric acid as the mobile phase at a flow rate of 0.7 mL / min. The injection volume was 10 μL. The column temperature was 50 ° C.

[0229] Lipid extraction and quantification

[0230] Fatty acids synthesized by Yarrowia lipolytica, including palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleate (C18:1), and linoleate (C18:2), were quantified using gas chromatography coupled with a flame ionization detector (GC-FID). 0.1-1 mL of cell culture was extracted from each bioreactor so that the sample contained approximately 1 mg of biomass. A centrifugation step was performed at 16,000 g for 10 minutes, and the supernatant was discarded. 0.5 mL of a 0.5 M sodium hydroxide-methanol solution (20 g / L sodium hydroxide in anhydrous methanol) was mixed with the cell pellet, and then 100 μL of an internal standard containing 2 mg / mL methyl tridecanoate (Sigma-Aldrich) and 2 mg / mL tris(tri ... The sample was vortexed for 1h to allow lipid transesterification to fatty acid methyl esters (FAME). Afterwards, 40 μL of 98% sulfuric acid (Sigma-Aldrich) was added to neutralize the pH value. FAME was then extracted by adding 0.5mL hexane and then vortexing for 30min. Then centrifugal 1min was performed at 12,000g to remove cell debris, and the top hexane layer was extracted for analysis. The separation of FAME species was achieved on an Agilent HP-INNOWax capillary column. The injection volume was 1 μL, the split ratio was 10, and the injection temperature was 260°C. The column was maintained at a constant temperature of 200°C, and helium was used as a carrier gas, wherein the flow rate was 1.5mL / min. The temperature setting of FID was 260°C, and the flow rates of helium supplementary gas, hydrogen and air were 25mL / min, 30mL / min and 300mL / min, respectively.

[0231] Intracellular metabolite extraction and quantification

[0232] In order to extract intracellular metabolites (such as IPP / DMAPP and GGPP), 1mL culture was filtered through a 25-mm 0.2 μm nylon filter using vacuum filtration. Immediately, the cells were washed with 2mL of water preheated to 30°C, and the filter was immersed in ice-cold extraction buffer (40% methanol + 40% acetonitrile + 20% water). After incubation at -20°C for 20min, the extract was centrifuged at 16,000rpm for 10 minutes, and the supernatant was transferred to a new tube and dried. The sample was resuspended with 50 μL of water, and then centrifuged at 16,000rpm for 10min. The metabolites in the supernatant were quantified by liquid chromatography-tandem mass spectrometry (LC-MS / MS) (including Agilent 1100 series LC systems and AB Sciex API-4000MS). 10 μL of sample was injected and separated on a Waters XBridge C-18 column, where the mobile phase consisted of solution A (0.1% tributylamine, 0.12% acetic acid, 0.5% 5M NH4OH in water, v / v) and solution B (100% acetonitrile). The flow rate was 0.3 mL / min, and the following gradient was used: 0-5 minutes, 0% B; 5-20 min, 0-65% B; 20-25 min, 65% B; 25-30 min, 100% B; 30-35 min, 100% B; 35-36 min; 100-0% B, 0% B until 45 min. The analytes were then compared to a standard curve generated using chemical standards purchased from Sigma-Aldrich and Cayman Chemicals.

[0233] Labeling experiment

[0234] The strains used in the labeling study were labeled with [U- 13 C] glucose as the sole carbon source in YNB medium. They were then subcultured in the same medium and grown at 30°C until early stationary phase. Samples were collected using the same intercellular metabolite extraction method before starting pulse addition of additional carbon source. Afterwards, 10 mM stearic acid was added to the corresponding cultures and metabolite isotopic enrichment was measured at different time points. The optical density associated with each sample was also recorded. IPP / DMAPP and GGPP were quantified by LC-MS / MS as described previously. All MS data in labeling experiments were natural abundance corrected using IsoCor (Millard et al., 2012).

[0235] Carotenoid extraction

[0236] Carotenoid extraction was performed as described (Asker et al., 2017) with the following modifications. Briefly, 100 μL of culture was centrifuged at 16,000 g for 1 min, and the cell pellet was suspended in 900 μL of dimethyl sulfoxide (DMSO, Sigma-Aldrich) and then heated at 50 °C for 1 h until the cells were bleached in a water bath. The DMSO extract was briefly mixed with 450 μL of methanol and centrifuged at 16,000 g for 5 min. The resulting supernatant was transferred to a 96-well assay plate or glass vial for carotenoid analysis and quantification.

[0237] Analysis and Quantification of Carotenoids

[0238] Carotenoid production was expressed as grams per liter of fermentation broth (g / L) and milligrams per gram of dry cell weight (mg / g DCW). The optical density at 600 nm was measured using a Thermo Spectronic Genesys 20 (Thermo Scientific) and used to calculate cell mass (for β-carotene, DCW = 0.35 × OD 600 , and for lycopene, DCW = 0.30 × OD 600 , Figures 40A-40B ). Analysis and quantification of β-carotene were performed using HPLC (SHIMADZU LC-20AT) equipped with a Kromasil C18 column (4.6 mm x 250 mm) and UV / VIS detection at 450 nm. The mobile phase consisted of acetonitrile-methanol-isopropanol (5:3:2 v / v) with a flow rate of 1 mL / min and a temperature of 40°C. Analysis and quantification of lycopene were performed using a Spectramax M2e microplate reader (Molecular devices) or HPLC at 470 nm. Standard curves for β-carotene and lycopene (Sigma-Aldrich) were prepared by running the same extraction process as for the samples.

[0239] Quantitative real-time PCR

[0240] Relative gene expression was assessed using real-time PCR (RT-PCR). TM Yeast RNA purification kit (Lucigen, Wisconsin, USA) was used as template and iScript TM RT-PCR was performed using a one-step RT-PCR kit and SYBR Green Supermix (Bio-Rad, USA) on an iCycler (Bio-Rad, USA) according to the manufacturer's instructions. ACT1 was used as an internal control gene for normalization. -△△CTor 2 -△CT Relative gene expression was calculated.

[0241] In vitro enzymatic assay

[0242] Yeast microsomes for in vitro enzymatic assays were prepared as previously described (Pompon et al., 1996). Briefly, strains containing wild-type or mutant CarRP were grown overnight at 30°C in YNB medium and then inoculated into 200 mL YNB medium to an initial OD of 600 0.1. After 24h cultivation, cells were collected by centrifugation at 4,000rpm for 10min. Cells were resuspended in TEK buffer (50mM Tris-HCl, pH 6.8, 1mM EDTA, 0.1M KCl), and the solution was then kept at room temperature for 5min. Afterwards, cells were recovered by centrifugation, washed with TES buffer (50mM Tris-HCl, pH 6.8, 1mMEDTA, 0.6M sorbitol), resuspended in TESM buffer (50mM Tris-HCl, pH 6.8, 1mM EDTA, 0.6M sorbitol, 14mM 2-mercaptoethanol), and placed at room temperature for 10min. Cells were then recovered by centrifugation again, washed in extraction buffer (50mM Tris-HCl, pH 6.8, 1mM EDTA, 1mM PMSF), and resuspended in extraction buffer. Glass beads were added to each sample, which were intermittently vortexed for 30 seconds and placed on ice for 30 seconds, for a total of 15 repetitions. The cell pellet was then discarded by centrifugation at 4,000rpm, 4°C for 10 minutes, and the supernatant was transferred to a 50mL tube. The crude yeast microsomal fraction collected above was used for in vitro determination of lycopene cyclase. Standard enzyme assays were performed in a total volume of 200μL solution containing 50mM Tris-HCl (pH 6.8), 1mM phenylmethylsulfonyl fluoride (PMSF) and 1mg of microsomal protein. Lycopene (50-350μmol / L) dissolved in dimethyl sulfoxide (DMSO) was used as a substrate. The reaction was started by adding the substrate, gently shaken and incubated at 30°C for 16h, and then terminated by adding 200μL of ethyl acetate. The solution was vortexed for 10min, and the organic phase was collected by centrifugation and analyzed by HPLC.

[0243] Generation of protein variants

[0244] By analyzing the amino acid conservation and co-evolution information in this protein family, variants are generated from the position-specific score matrix (PSSM). This paper uses the psiblast generation matrix in ncbi-blast-2.7.1+ (Altschul et al., 1997), with uniref90 (Suzek et al., 2007) as the database, and the E value is 0.01, running 3 iterations. For all positions in the protein, the PSSM scores of both lycopene cyclase and other homologous proteins in the family are calculated, which represent the conservation of amino acids. The higher the score, the more conservative the amino acid at the position. The substitutions (substitutions) that can be substituted with more conservative amino acids according to the PSSM score are screened out. The difference value between the potential substitution and the wild-type amino acid is calculated, and the scores are classified. All glycine substitutions are removed from the score. The 25 highest-scoring substitutions are randomly combined into double substitutions. The distance matrix is ​​calculated using the PAM30 substitution matrix, and the agglomeration hierarchy in sklearn (Pedregosa et al., 2011) is clustered into 25 clusters to minimize the number of tests. Variants are randomly selected within each cluster. Scoring substitutions ranked 26-50 were ranked as single mutation variants.

[0245] Homology model of lycopene cyclase

[0246] A homology model of lycopene cyclase was generated using the TrRosetta server ( Yang et al., 2020 ), and the sequence of the R domain (1–239 amino acids) of CarRP was submitted.

[0247] Calculation of C / N ratio in culture medium

[0248] Reference BD Bionutrients TM Technical Manual (Table 10) legacy.bd.com / ds / technicalCenter / misc / lcn01558-bionutrients-manual.pdf Yeast extract (Bacto TM ) and peptone (Bacto TM ) was used to calculate the C / N ratio. The carbon in yeast extract and peptone was ignored because of their extremely low concentrations relative to glucose. The total nitrogen in yeast extract and peptone was 10.9% and 15.4%, respectively. The C / N ratio was generated using the following formula. X, Y, and Z represent the concentrations of glucose, yeast extract, and peptone, respectively.

[0249]

[0250] Table 6. List of heterologous enzymes used in Example 5.

[0251]

[0252]

[0253] Table 7. Strains and constructs used in Example 5.

[0254]

[0255]

[0256] Table 8. Overview of carotenoid production in microorganisms.

[0257]

[0258] a Productivity was calculated as total carotenoids produced divided by total fermentation time.

[0259] Table 9. Primers used in Example 5.

[0260]

[0261]

[0262]

[0263] Table 10. Yeast extract (Bacto TM ) and peptone (Bacto TM ) composition.

[0264]

[0265] References:

[0266] 1. Menchik, P.; Zuber, T.; Zuber, A.; Moraru, CIShort Communication: Composition of Coproduct Streams from Dairy Processing: Acid Whey and MilkPermeate.

[0267] 2. Lievore, P.; D.R.S.;Silva,K.M.;Drunkler,N.L.;Barana,A.C.;Nogueira,A.;Demiate,I.M.Chemical Characterisation and Application of AcidWhey in Fermented Milk.J.Food Sci.Technol.2015,52(4),2083–2092.doi.org / 10.1007 / s13197-013-1244-z.

[0268] 3.Lindsay,M.J.;Walker,T.W.;Dumesic,J.A.;Rankin,S.A.;Huber,G.W.Production of Monosaccharides and Whey Protein from Acid Whey WasteStreams in the Dairy Industry.Green Chem.2018,20(8),1824–1834.doi.org / 10.1039 / c8gc00517f.

[0269] 4.Xu,J.;Hao,J.;Guzman,J.J.L.;Spirito,C.M.;Harroff,L.A.;Angenent,L.T.Temperature-Phased Conversion of Acid Whey Waste Into Medium-ChainCarboxylic Acids via Lactic Acid:No External e-Donor.Joule 2018,2(2),280–295.doi.org / 10.1016 / j.joule.2017.11.008.

[0270] 5.Bentahar,J.;Doyen,A.;Beaulieu,L.;Deschênes,J.S.Acid Whey Permeate:An Alternative Growth Medium for Microalgae Tetradesmus Obliquus andProduction ofβ-Galactosidase.Algal Res.2019,41,101559.doi.org / 10.1016 / j.algal.2019.101559.

[0271] 6.Fischer,C.;Kleinschmidt,T.Synthesis of GalactooligosaccharidesUsing Sweet and Acid Whey as a Substrate.Int.Dairy J.2015,48,15–22.doi.org / 10.1016 / j.idairyj.2015.01.003.

[0272] 7.Skryplonek,K.;Dmytrów,I.;Mituniewicz- A.Probiotic FermentedBeverages Based on Acid Whey.J.Dairy Sci.2019,102(9),7773–7780.doi.org / 10.3168 / jds.2019-16385.

[0273] 8.Carotenoids Market|2020-2027|Industry Report|Covid Insightsmordorintelligence.com / industry-reports / carotenoids-market-industry(accessedFeb 18,2021).

[0274] 9.Mano,J.;Liu,N.;Hammond,J.H.;Currie,D.H.;Stephanopoulos,G.Engineering Yarrowia Lipolytica for the Utilization of AcidWhey.Metab.Eng.2020,57,43–50.doi.org / 10.1016 / j.ymben.2019.09.010.

[0275] 10.Larroude,M.;Celinska,E.;Back,A.;Thomas,S.;Nicaud,J.M.;Ledesma-Amaro,R.A Synthetic Biology Approach to Transform Yarrowia Lipolytica into aCompetitive Biotechnological Producer ofβ-Carotene.Biotechnol.Bioeng.2018,115(2),464–472.doi.org / 10.1002 / bit.26473.

[0276] 11.Yamada,E.A.;Sgarbieri,V.C.Yeast(Saccharomyces Cerevisiae)ProteinConcentrate:Preparation,Chemical Composition,and Nutritional and FunctionalProperties.J.Agric.Food Chem.2005,53(10),3931–3936.doi.org / 10.1021 / jf0400821.

[0277] 12. F.A.G.;Colen,G.;Takahashi,J.A.Yarrowia Lipolytica and ItsMultiple Applications in the Biotechnological Industry.Sci.World J.2014,2014.doi.org / 10.1155 / 2014 / 476207.

[0278] 13.Qiao,K.;Abidi,S.H.I.;Liu,H.;Zhang,H.;Chakraborty,S.;Watson,N.;Ajikumar,P.K.;Stephanopoulos,G.Engineering Lipid Overproduction in theOleaginous Yeast Yarrowia Lipolytica.Metab.Eng.2015,29,56–65.doi.org / 10.1016 / j.ymben.2015.02.005.14.Tai,M.;Stephanopoulos,G.Engineering the Push and Pullof Lipid Biosynthesis in Oleaginous Yeast Yarrowia Lipolytica for BiofuelProduction.Metab.Eng.2013,15(1),1–9.doi.org / 10.1016 / j.ymben.2012.08.007.

[0279] 15.U.S.Greek Yogurt Market-Statistics&Facts|Statista.statista.com / topics / 2351 / greek-yogurt / .

[0280] 16.Menchik,P.,Zuber,T.,Zuber,A.&Moraru,C.I.Short communication:Composition of coproduct streams from dairy processing:Acid whey and milkpermeate.J.Dairy Sci.102,3978–3984(2019).

[0281] 17.Lievore,P.et al.Chemical characterisation and application of acidwhey in fermented milk.J.Food Sci.Technol.52,2083–2092(2015).

[0282] 18.Maoka,T.Carotenoids as natural functional pigments.Journal ofNatural Medicines vol.741–16(2020).

[0283] 19.Bogacz-Radomska,L.&Harasym,J.β-Carotene—properties and productionmethods.Food Qual.Saf.2,69–74(2018).

[0284] 20.Li,C.,Swofford,C.A.&Sinskey,A.J.Modular engineering for microbialproduction of carotenoids.Metabolic Engineering Communications vol.10 e00118(2020).

[0285] 21.Mano,J.,Liu,N.,Hammond,J.H.,Currie,D.H.&Stephanopoulos,G.Engineering Yarrowia lipolytica for the utilization of acidwhey.Metab.Eng.57,43–50(2020).

[0286] 22.Anselmo,A.C.et al.A heat-stable microparticle platform for oralmicronutrient delivery.Sci.Transl.Med.11,(2019).

[0287] 23.Tai,M.&Stephanopoulos,G.Engineering the push and pull of lipidbiosynthesis in oleaginous yeast Yarrowia lipolytica for biofuelproduction.Metab.Eng.15,1–9(2013).

[0288] 24.Xu,P.,Qiao,K.,Ahn,W.S.&Stephanopoulos,G.Engineering Yarrowialipolytica as a platform for synthesis of drop-in transportation fuels and oleochemicals.Proc.Natl.Acad.Sci.U.S.A.113,10848–10853(2016).

[0289] 25.Qiao,K.,Wasylenko,T.M.,Zhou,K.,Xu,P.&Stephanopoulos,G.Lipidproduction in Yarrowia lipolytica is maximized by engineering cytosolic redoxmetabolism.Nat.Biotechnol.35,173–177(2017).

[0290] 26.Qiao,K.et al.Engineering lipid overproduction in the oleaginousyeast Yarrowia lipolytica.Metab.Eng.29,56–65(2015).

[0291] 27.Luo,Z.et al.Enhancing isoprenoid synthesis in Yarrowia lipolyticaby expressing the isopentenol utilization pathway and modulatingintracellular hydrophobicity.Metab.Eng.61,344–351(2020).

[0292] 28.Larroude,M.et al.A synthetic biology approach to transformYarrowia lipolytica into a competitive biotechnological producer ofβ-carotene.Biotechnol.Bioeng.115,464–472(2018).

[0293] 29.Groenewald,M.et al.Yarrowia lipolytica:Safety assessment of anoleaginous yeast with a great industrial potential.Critical Reviews inMicrobiology vol.40 187–206(2014)

[0294] 30.Carotenoids Market|2020-2027|Industry Report|CovidInsights.mordorintelligence.com / industry-reports / carotenoids-market-industry.

[0295] 31.Carotenoids Market Size,Revenue|Global Industry Trends[2020-2027].fortunebusinessinsights.com / industry-reports / carotenoids-market-100180.

[0296] 32.Groenewald,M.et al.Yarrowia lipolytica:Safety assessment of anoleaginous yeast with a great industrial potential.Critical Reviews inMicrobiology vol.40 187–206(2014).33.Xue,Z.et al.Production of omega-3eicosapentaenoic acid by metabolic engineering of Yarrowialipolytica.Nat.Biotechnol.31,734–740(2013).

[0297] 34.Xie,D.,Jackson,E.N.&Zhu,Q.Sustainable source of omega-3eicosapentaenoic acid from metabolically engineered Yarrowia lipolytica:fromfundamental research to commercial production.Appl.Microbiol.Biotechnol.99,1599–1610(2015).

[0298] 35.Ritala,A., S.T.,Toivari,M.&Wiebe,M.G.Single Cell Protein—State-of-the-Art,Industrial Landscape and Patents 2001–2016.Front.Microbiol.8,2009(2017).

[0299] 36.Lindsay,M.J.,Walker,T.W.,Dumesic,J.A.,Rankin,S.A.&Huber,G.W.Production of monosaccharides and whey protein from acid whey wastestreams in the dairy industry.Green Chem.20,1824–1834(2018).

[0300] 37.Xu,J.et al.Temperature-Phased Conversion of Acid Whey Waste IntoMedium-Chain Carboxylic Acids via Lactic Acid:No External e-Donor.Joule 2,280–295(2018).

[0301] 38.Bentahar,J.,Doyen,A.,Beaulieu,L.&Deschênes,J.S.Acid whey permeate:An alternative growth medium for microalgae Tetradesmus obliquus andproduction ofβ-galactosidase.Algal Res.41,101559(2019).

[0302] 39.Fischer,C.&Kleinschmidt,T.Synthesis of galactooligosaccharidesusing sweet and acid whey as a substrate.Int.Dairy J.48,15–22(2015).

[0303] 40.Skryplonek,K.,Dmytrów,I.&Mituniewicz- A.Probiotic fermentedbeverages based on acid whey.J.Dairy Sci.102,7773–7780(2019).

[0304] 41.Xu,P.,Qiao,K.&Stephanopoulos,G.Engineering oxidative stressdefense pathways to build a robust lipid production platform in Yarrowia lipolytica.Biotechnol.Bioeng.114,1521–1530(2017).

[0305] 42.Heinzle,E.et al.Ecological and economic objective functions forscreening in integrated development of fine chemical processes.1.Flexible andexpandable framework using indices.Ind.Eng.Chem.Res.37,3395–3407(1998).

[0306] 43.Abdel-Mawgoud,A.M.,Markham,K.A.,Palmer,C.M.,Liu,N.,Stephanopoulos,G.,Alper,H.S.,2018.Metabolic engineering in the host Yarrowialipolytica.Metab.Eng.50,192-208.

[0307] 44.Ajikumar,P.K.,Xiao,W.-H.,Tyo,K.E.,Wang,Y.,Simeon,F.,Leonard,E.,Mucha,O.,Phon,T.H.,Pfeifer,B.,Stephanopoulos,G.,2010.Isoprenoid pathwayoptimization for Taxol precursor overproduction in Escherichiacoli.Science.330,70-74.

[0308] 45.Ambati,R.R.,Phang,S.-M.,Ravi,S.,Aswathanarayana,R.G.,2014.Astaxanthin:sources,extraction,stability,biological activities and itscommercial applications—a review.Mar.Drugs.12,128-152.

[0309] 46.Asker,D.,2017.Isolation and characterization of a novel,highlyselective astaxanthin-producing marine bacterium.J.Agric.Food.Chem.65,9101-9109.

[0310] 47.Atanasov,A.G.,Waltenberger,B.,Pferschy-Wenzig,E.-M.,Linder,T.,Wawrosch,C.,Uhrin,P.,Temml,V.,Wang,L.,Schwaiger,S.,Heiss,E.H.,2015.Discoveryand resupply of pharmacologically active plant-derived natural products:Areview.Biotechnol.Adv.33,1582-1614.

[0311] 48.Avalos,J.L.,Fink,G.R.,Stephanopoulos,G.,2013.Compartmentalizationof metabolic pathways in yeast mitochondria improves the production ofbranched-chain alcohols.Nat.Biotechnol.31,335.

[0312] 49.Ayer,A.,Sanwald,J.,Pillay,B.A.,Meyer,A.J.,Perrone,G.G.,Dawes,I.W.,2013.Distinct redox regulation in sub-cellular compartments in response tovarious stress conditions in Saccharomyces cerevisiae.PLoS One.8.

[0313] 50.Bayer,T.S.,Widmaier,D.M.,Temme,K.,Mirsky,E.A.,Santi,D.V.,Voigt,C.A.,2009.Synthesis of methyl halides from biomass using engineeredmicrobes.J.Am.Chem.Soc.131,6508-6515.

[0314] 51.Bennedsen,M.,Wang,X.,Willén,R., T.,Andersen,L.P.,2000.Treatment of H.pylori infected mice with antioxidant astaxanthin reducesgastric inflammation,bacterial load and modulates cytokine release bysplenocytes.Immunol.Lett.70,185-189.

[0315] 52.Cao,X.,Yang,S.,Cao,C.,Zhou,Y.J.,2020.Harnessing sub-organellemetabolism for biosynthesis of isoprenoids in yeast.Synth.Syst.Biotechnol.5,179-186.

[0316] 53.Chang,J.-J.,Thia,C.,Lin,H.-Y.,Liu,H.-L.,Ho,F.-J.,Wu,J.-T.,Shih,M.-C.,Li,W.-H.,Huang,C.-C.,2015.Integrating an algalβ-carotene hydroxylase geneinto a designed carotenoid-biosynthesis pathway increases carotenoidproduction in yeast.Bioresour.Technol.184,2-8.

[0317] 54.Chemler,J.A.,Koffas,M.A.,2008.Metabolic engineering for plantnatural product biosynthesis in microbes.Curr.Opin.Biotechnol.19,597-605.

[0318] 55.Chew,B.,Park,J.,Wong,M.,Wong,T.,1999.A comparison of theanticancer activities of dietary beta-carotene,canthaxanthin and astaxanthinin mice in vivo.Anticancer Res.19,1849-1853.

[0319] 56.Choi,S.-k.,Nishida,Y.,Matsuda,S.,Adachi,K.,Kasai,H.,Peng,X.,Komemushi,S.,Miki,W.,Misawa,N.,2005.Characterization ofβ-Carotene Ketolases,CrtW,from Marine Bacteria by Complementation Analysis in Escherichiacoli.Mar.Biotechnol.7,515-522.

[0320] 57.Cragg,G.M.,1998.Paclitaxel a success story with valuablelessons for natural product drug discovery and development.Med.Res.Rev.18,315-331.

[0321] 58.Dhingra,V.,Rao,K.V.,Narasu,M.L.,1999.Current status of artemisininand its derivatives as antimalarial drugs.Life Sci.66,279-300.

[0322] 59.Diao,J.,Song,X.,Zhang,L.,Cui,J.,Chen,L.,Zhang,W.,2020.Tailoringcyanobacteria as a new platform for highly efficient synthesis ofastaxanthin.Metab.Eng.60.Dzubak,P.,Hajduch,M.,Vydra,D.,Hustova,A.,Kvasnica,M.,Biedermann,D.,Markova,L.,Urban,M.,Sarek,J.,2006.Pharmacological activitiesof natural triterpenoids and their therapeutic implications.Nat.Prod.Rep.23,394-411.

[0323] 61.Farhi,M.,Marhevka,E.,Masci,T.,Marcos,E.,Eyal,Y.,Ovadis,M.,Abeliovich,H.,Vainstein,A.,2011.Harnessing yeast subcellular compartments forthe production of plant terpenoids.Metab.Eng.13,474-481.

[0324] 62.Gong,Z.,Wang,H.,Tang,J.,Bi,C.,Li,Q.,Zhang,X.,2020.Coordinatedexpression of astaxanthin biosynthesis genes for improved astaxanthinproduction in Escherichia coli.J.Agric.Food.Chem.68,14917-14927.

[0325] 63.Hama,S.,Takahashi,K.,Inai,Y.,Shiota,K.,Sakamoto,R.,Yamada,A.,Tsuchiya,H.,Kanamura,K.,Yamashita,E.,Kogure,K.,2012.Protective effects oftopical application of a poorly soluble antioxidant astaxanthin liposomalformulation on ultraviolet-induced skin damage.J.Pharm.Sci.101,2909-2916.

[0326] 64.Hammer,S.K.,Avalos,J.L.,2017.Harnessing yeast organelles formetabolic engineering.Nat.Chem.Biol.13,823.

[0327] 65.Henke,N.A.,Wiebe,D.,Pérez-García,F.,Peters-Wendisch,P.,Wendisch,V.F.,2018.Coproduction of cell-bound and secreted value-added compounds:Simultaneous production of carotenoids and amino acids by Corynebacterium glutamicum.Bioresour.Technol.247,744-752.

[0328] 66.Jiang,G.,Yang,Z.,Wang,Y.,Yao,M.,Chen,Y.,Xiao,W.,Yuan,Y.,2020.Enhanced astaxanthin production in yeast via combined mutagenesis andevolution.Biochem.Eng.J.156,107519.

[0329] 67.Jin,J.,Wang,Y.,Yao,M.,Gu,X.,Li,B.,Liu,H.,Ding,M.,Xiao,W.,Yuan,Y.,2018.Astaxanthin overproduction in yeast by strain engineering and new genetarget uncovering.Biotechnol.Biofuels.11,230.

[0330] 68.Kildegaard,K.R.,Adiego-Pérez,B.,Belda,D.D.,Khangura,J.K.,Holkenbrink,C.,Borodina,I.,2017.Engineering of Yarrowia lipolytica forproduction of astaxanthin.Synth.Syst.Biotechnol.2,287-294.

[0331] 69.Larroude,M.,Celinska,E.,Back,A.,Thomas,S.,Nicaud,J.M.,Ledesma-Amaro,R.,2018.A synthetic biology approach to transform Yarrowia lipolyticainto a competitive biotechnological producer ofβ-carotene.Biotechnol.Bioeng.115,464-472.

[0332] 70.Lemuth,K.,Steuer,K.,Albermann,C.,2011.Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis ofastaxanthin.Microb.Cell Fact.10,29.

[0333] 71.Li,N.,Han,Z.,O’Donnell,T.J.,Kurasaki,R.,Kajihara,L.,Williams,P.G.,Tang,Y.,Su,W.W.,2020.Production and excretion of astaxanthin by engineered Yarrowia lipolytica using plant oil as both the carbon source and thebiocompatible extractant.Appl.Microbiol.Biotechnol.,1-13.

[0334] 72.Liu,G.-S.,Li,T.,Zhou,W.,Jiang,M.,Tao,X.-Y.,Liu,M.,Zhao,M.,Ren,Y.-H.,Gao,B.,Wang,F.-Q.,2020.The yeast peroxisome:A dynamic storage depot andsubcellular factory for squalene overproduction.Metab.Eng.57,151-161.

[0335] 73.Lu,Q.,Bu,Y.-F.,Liu,J.-Z.,2017.Metabolic engineering of Escherichiacoli for producing astaxanthin as the predominant carotenoid.Mar.Drugs.15,296.

[0336] 74.Ma,T.,Zhou,Y.,Li,X.,Zhu,F.,Cheng,Y.,Liu,Y.,Deng,Z.,Liu,T.,2016.Genome mining of astaxanthin biosynthetic genes from Sphingomonassp.ATCC 55669 for heterologous overproduction in Escherichiacoli.Biotechnology journal.11,228-237.

[0337] 75.Martin,V.J.,Pitera,D.J.,Withers,S.T.,Newman,J.D.,Keasling,J.D.,2003.Engineering a mevalonate pathway in Escherichia coli for production ofterpenoids.Nat.Biotechnol.21,796-802.

[0338] 76.Nogueira,M.,Enfissi,E.M.A.,Welsch,R.,Beyer,P.,Zurbriggen,M.D.,Fraser,P.D.,2019.Construction of a fusion enzyme for astaxanthin formationand its characterisation in microbial and plant hosts:A new tool forengineering ketocarotenoids.Metab.Eng.52,243-252.

[0339] 77.Park,S.Y.,Binkley,R.M.,Kim,W.J.,Lee,M.H.,Lee,S.Y.,2018.Metabolicengineering of Escherichia coli for high-level astaxanthin production withhigh productivity.Metab.Eng.49,105-115.

[0340] 78.Qi,D.-D.,Jin,J.,Liu,D.,Jia,B.,Yuan,Y.-J.,2020.In vitro and in vivorecombination of heterologous modules for improving biosynthesis ofastaxanthin in yeast.Microb.Cell Fact.19,1-12.

[0341] 79.Scaife,M.A.,Burja,A.M.,Wright,P.C.,2009.Characterization ofcyanobacterialβ-carotene ketolase and hydroxylase genes in Escherichia coli,and their application for astaxanthin biosynthesis.Biotechnol.Bioeng.103,944-955.

[0342] 80.Scaife,M.A.,Ma,C.A.,Ninlayarn,T.,Wright,P.C.,Armenta,R.E.,2012.Comparative analysis ofβ-carotene hydroxylase genes for astaxanthinbiosynthesis.J.Nat.Prod.75,1117-1124.

[0343] 81.Sheng,J.,Stevens,J.,Feng,X.,2016.Pathway compartmentalization inperoxisome of Saccharomyces cerevisiae to produce versatile medium chainfatty alcohols.Sci.Rep.6,1-11.

[0344] 82.Szczebara,F.M.,Chandelier,C.,Villeret,C.,Masurel,A.,Bourot,S.,Duport,C.,Blanchard,S.,Groisillier,A.,Testet,E.,Costaglioli,P.,2003.Totalbiosynthesis of hydrocortisone from a simple carbon source inyeast.Nat.Biotechnol.21,143-149.

[0345] 83.Thodey,K.,Galanie,S.,Smolke,C.D.,2014.A microbial biomanufacturingplatform for natural and semisynthetic opioids.Nat.Chem.Biol.10,837.

[0346] 84.Tramontin,L.R.R.,Kildegaard,K.R.,Sudarsan,S.,Borodina,I.,2019.Enhancement of astaxanthin biosynthesis in oleaginous yeast Yarrowialipolytica via microalgal pathway.Microorganisms.7,472.

[0347] 85.Ukibe,K.,Hashida,K.,Yoshida,N.,Takagi,H.,2009.Metabolicengineering of Saccharomyces cerevisiae for astaxanthin production andoxidative stress tolerance.Appl.Environ.Microbiol.75,7205-7211.

[0348] 86.Wang,R.,Gu,X.,Yao,M.,Pan,C.,Liu,H.,Xiao,W.,Wang,Y.,Yuan,Y.,2017.Engineering ofβ-carotene hydroxylase and ketolase for astaxanthinoverproduction in Saccharomyces cerevisiae.Front.Chem.Sci.Eng.11,89-99.

[0349] 87.Xu,P.,Qiao,K.,Ahn,W.S.,Stephanopoulos,G.,2016.Engineering Yarrowialipolytica as a platform for synthesis of drop-in transportation fuels and oleochemicals.Proc.Natl.Acad.Sci.USA.113,10848-10853.

[0350] 88.Yang,K.,Qiao,Y.,Li,F.,Xu,Y.,Yan,Y.,Madzak,C.,Yan,J.,2019.Subcellular engineering of lipase dependent pathways directed towardslipid related organelles for highly effectively compartmentalizedbiosynthesis of triacylglycerol derived products in Yarrowialipolytica.Metab.Eng.55,231-238.

[0351] 89.Yuan,J.,Ching,C.-B.,2016.Mitochondrial acetyl-CoA utilizationpathway for terpenoid productions.Metab.Eng.38,303-309.

[0352] 90.Zhang,C.,Seow,V.Y.,Chen,X.,Too,H.-P.,2018.Multidimensionalheuristic process for high-yield production of astaxanthin and fragrancemolecules in Escherichia coli.Nat.Commun.9,1858.

[0353] 91.Zhou,P.,Li,M.,Shen,B.,Yao,Z.,Bian,Q.,Ye,L.,Yu,H.,2019.Directedcoevolution ofβ-carotene ketolase and hydroxylase and its application intemperature-regulated biosynthesis of astaxanthin.J.Agric.Food.Chem.67,1072-1080.

[0354] 92.Zhou,P.,Xie,W.,Li,A.,Wang,F.,Yao,Z.,Bian,Q.,Zhu,Y.,Yu,H.,Ye,L.,2017.Alleviation of metabolic bottleneck by combinatorial engineeringenhanced astaxanthin synthesis in Saccharomyces cerevisiae.EnzymeMicrob.Technol.100,28-36.

[0355] 93.Zhou,P.,Ye,L.,Xie,W.,Lv,X.,Yu,H.,2015.Highly efficientbiosynthesis of astaxanthin in Saccharomyces cerevisiae by integration andtuning of algal crtZ and bkt.Appl.Microbiol.Biotechnol.99,8419-8428.

[0356] 94.Zhou,X.,Gong,Z.,Su,Y.,Lin,J.,Tang,K.,2009.Cordyceps fungi:naturalproducts,pharmacological functions and developmentalproducts.J.Pharm.Pharmacol.61,279-291.

[0357] 95.Zhou,Y.J.,Buijs,N.A.,Zhu,Z.,Gómez,D.O.,Boonsombuti,A.,Siewers,V.,Nielsen,J.,2016.Harnessing yeast peroxisomes for biosynthesis of fatty-acid-derived biofuels and chemicals with relieved side-pathwaycompetition.J.Am.Chem.Soc.138,15368-15377.

[0358] 96.Chen Y,Nielsen J.Advances in metabolic pathway and strainengineering paving the way for sustainable production of chemical buildingblocks.Curr.Opin.Biotechnol.24,965-972(2013).

[0359] 97.Li Y,Smolke CD.Engineering biosynthesis of the anticancer alkaloidnoscapine in yeast.Nat.Commun.7,12137(2016).

[0360] 98.Liu Y,Nielsen J.Recent trends in metabolic engineering ofmicrobial chemical factories.Curr.Opin.Biotechnol.60,188-197(2019).

[0361] 99.Wu G,Yan Q,Jones JA,Tang YJ,Fong SS,Koffas MA.Metabolic burden:cornerstones in synthetic biology and metabolic engineeringapplications.Trends Biotechnol.34,652-664(2016).

[0362] 100.Keasling JD.Manufacturing molecules through metabolicengineering.Science 330,1355-1358(2010).

[0363] 101.Reed MC,Lieb A,Nijhout HF.The biological significance ofsubstrate inhibition:a mechanism with diverse functions.Bioessays 32,422-429(2010).

[0364] 102.Boutin JA,Chatelain-Egger F,Vella F,Delagrange P,Ferry G.Quinonereductase 2substrate specificity and inhibition pharmacology.Chem.Biol.Interact.151,213-228(2005).

[0365] 103.Belzer M,Morales M,Jagadish B,Mash EA,Wright SH.Substrate-dependent ligand inhibition of the human organic cation transporterOCT2.J.Pharmacol.Exp.Ther.346,300-310(2013).

[0366] 104.Singh RK,Tiwari MK,Singh R,Lee J-K.From protein engineering toimmobilization:promising strategies for the upgrade of industrialenzymes.Int.J.Mol.Sci.14,1232-1277(2013).

[0367] 105.Mateo C,et al.Immobilization of lactase from Kluyveromyces lactisgreatly reduces the inhibition promoted by glucose.Full hydrolysis of lactosein milk.Biotechnol.Prog.20,1259-1262(2004).

[0368] 106.Daugulis AJ,Tomei MC,Guieysse B.Overcoming substrate inhibitionduring biological treatment of monoaromatics:recent advances in bioprocess design.Appl.Microbiol.Biotechnol.90,1589-1608(2011).

[0369] 107.Gao F,Daugulis AJ.Bioproduction of the aroma compound 2-phenylethanol in a solid–liquid two-phase partitioning bioreactor system byKluyveromyces marxianus.Biotechnol.Bioeng.104,332-339(2009).

[0370] 108.Nielsen DR,Amarasiriwardena GS,Prather KL.Predicting theadsorption of second generation biofuels by polymeric resins withapplications for in situ product recovery(ISPR).Bioresour.Technol.101,2762-2769(2010).

[0371] 109.Kim PY,Pollard DJ,Woodley JM.Substrate supply for effectivebiocatalysis.Biotechnol.Prog.23,74-82(2007).

[0372] 110.Chen C,et al.Structure-based mutational studies of substrateinhibition of betaine aldehyde dehydrogenase BetB from Staphylococcus aureus.Appl.Environ.Microbiol.80,3992-4002(2014).

[0373] 111.Shang Y-P,Chen Q,Li A-T,Quan S,Xu J-H,Yu H-L.Attenuated substrateinhibition of a haloketone reductase via structure-guided loopengineering.J.Biotechnol.308,141-147(2020).

[0374] 112.Verdoes JC,Misawa N,van Ooyen AJ.Cloning and characterization ofthe astaxanthin biosynthetic gene encoding phytoene desaturase ofXanthophyllomyces dendrorhous.Biotechnol.Bioeng.63,750-755(1999).

[0375] 113.Verdoes J,Krubasik P,Sandmann G,Van Ooyen A.Isolation andfunctional characterisation of a novel type of carotenoid biosynthetic genefrom Xanthophyllomyces dendrorhous.Mol.Gen.Genet.262,453-461(1999).

[0376] 114.Velayos A,Blasco JL,Alvarez MI,Iturriaga EA,Eslava AP.Blue-lightregulation of phytoene dehydrogenase(carB)gene expression in Mucorcircinelloides.Planta 210,938-946(2000).

[0377] 115.Velayos A,Eslava AP,Iturriaga EA.A bifunctional enzyme withlycopene cyclase and phytoene synthase activities is encoded by the carRPgene of Mucor circinelloides.Eur.J.Biochem.267,5509-5519(2000).

[0378] 116.Yang J,Anishchenko I,Park H,Peng Z,Ovchinnikov S,Baker D.Improvedprotein structure prediction using predicted interresidue orientations.Proc.Natl.Acad.Sci.USA 117,1496-1503(2020).

[0379] 117.Ro D-K,et al.Production of the antimalarial drug precursorartemisinic acid in engineered yeast.Nature 440,940-943(2006).

[0380] 118.Westfall PJ,et al.Production of amorphadiene in yeast,and itsconversion to dihydroartemisinic acid,precursor to the antimalarial agent artemisinin.Proc.Natl.Acad.Sci.USA 109,E111-E118(2012).

[0381] 119.Chatzivasileiou AO,Ward V,Edgar SM,Stephanopoulos G.Two-steppathway for isoprenoid synthesis.Proc.Natl.Acad.Sci.USA 116,506-511(2019).

[0382] 120.Clomburg JM,Qian S,Tan Z,Cheong S,Gonzalez R.The isoprenoidalcohol pathway,a synthetic route for isoprenoid biosynthesis.Proc.Natl.Acad.Sci.USA 116,12810-12815(2019).

[0383] 121.Rico J,et al.Exploring natural biodiversity to expand access tomicrobial terpene synthesis.Microb.Cell Fact.18,23(2019).

[0384] 122.Lund S,Hall R,Williams GJ.An artificial pathway for isoprenoidbiosynthesis decoupled from native hemiterpene metabolism.ACS Synth.Biol.8,232-238(2019).

[0385] 123.Qiao K,Wasylenko TM,Zhou K,Xu P,Stephanopoulos G.Lipid productionin Yarrowia lipolytica is maximized by engineering cytosolic redoxmetabolism.Nat.Biotechnol.35,173(2017).

[0386] 124.Ma T,et al.Lipid engineering combined with systematic metabolicengineering of Saccharomyces cerevisiae for high-yield production oflycopene.Metab.Eng.52,134-142(2019).

[0387] 125.Larroude M,Celinska E,Back A,Thomas S,Nicaud JM,Ledesma-Amaro R.Asynthetic biology approach to transform Yarrowia lipolytica into acompetitive biotechnological producer ofβ-carotene.Biotechnol.Bioeng.115,464-472(2018).

[0388] 126.Braunwald T,et al.Effect of different C / N ratios on carotenoidand lipid production by Rhodotorula glutinis.Appl.Microbiol.Biotechnol.97,6581-6588(2013).

[0389] 127.Somashekar D,Joseph R.Inverse relationship between carotenoid andlipid formation in Rhodotorula gracilis according to the C / N ratio of thegrowth medium.World J.Microbiol.Biotechnol.16,491-493(2000).

[0390] 128.Wang W,et al.Harnessing the intracellular triacylglycerols fortiter improvement of polyketides in Streptomyces.Nat.Biotechnol.38,76-83(2020).

[0391] 129.Xu P,Qiao K,Ahn WS,Stephanopoulos G.Engineering Yarrowialipolytica as a platform for synthesis of drop-in transportation fuels and oleochemicals.Proc.Natl.Acad.Sci.USA 113,10848-10853(2016).

[0392] 130.Reetz MT.Biocatalysis in organic chemistry and biotechnology:past,present,and future.J.Am.Chem.Soc.135,12480-12496(2013).

[0393] 131.Tan SZ,Manchester S,Prather KL.Controlling central carbonmetabolism for improved pathway yields in Saccharomyces cerevisiae.ACSSynth.Biol.5,116-124(2016).132.Zhao EM,et al.Optogenetic regulation ofengineered cellular metabolism for microbial chemical production.Nature 555,683(2018).

[0394] 133.Brockman IM,Prather KL.Dynamic knockdown ofE.coli centralmetabolism for redirecting fluxes of primary metabolites.Metab.Eng.28,104-113(2015).

[0395] 134.Schwartz CM,Hussain MS,Blenner M,Wheeldon I.Synthetic RNApolymerase III promoters facilitate high-efficiency CRISPR–Cas9-mediatedgenome editing in Yarrowia lipolytica.ACS Synth.Biol.5,356-359(2016).

[0396] 135.Millard P,Letisse F,Sokol S,Portais J-C.IsoCor:correcting MS datain isotope labeling experiments.Bioinformatics 28,1294-1296(2012).

[0397] 136.Asker D.Isolation and characterization of a novel,highlyselective astaxanthin-producing marine bacterium.J.Agric.Food.Chem.65,9101-9109(2017).

[0398] 137.Pompon D,Louerat B,Bronine A,Urban P.Yeast expression of animaland plant P450s in optimized redox environments.Methods Enzymol.272,51-64(1996).

[0399] 138.Altschul SF,et al.Gapped BLAST and PSI-BLAST:a new generation ofprotein database search programs.Nucleic Acids Res.25,3389-3402(1997).

[0400] 139.Suzek BE,Huang H,McGarvey P,Mazumder R,Wu CH.UniRef:comprehensiveand non-redundant UniProt reference clusters.Bioinformatics 23,1282-1288(2007).

[0401] 140.Pedregosa F,et al.Scikit-learn:Machine learning inPython.J.Mach.Learn.Res.12,2825-2830(2011).

[0402] 141.Guindon S,Dufayard J-F,Lefort V,Anisimova M,Hordijk W,GascuelO.New algorithms and methods to estimate maximum-likelihood phylogenies:assessing the performance of PhyML 3.0.Syst.Biol.59,307-321(2010).

[0403] 142.Larroude M,Celinska E,Back A,Thomas S,Nicaud JM,Ledesma-Amaro R.Asynthetic biology approach to transform Yarrowia lipolytica into acompetitive biotechnological producer ofβ-carotene.Biotechnol.Bioeng.115,464-472(2018).

[0404] 143.Gao S,et al.Iterative integration of multiple-copy pathway genesin Yarrowia lipolytica for heterologousβ-carotene production.Metab.Eng.41,192-201(2017).

[0405] 144.Xie W,Ye L,Lv X,Xu H,Yu H.Sequential control of biosyntheticpathways for balanced utilization of metabolic intermediates in Saccharomycescerevisiae.Metab.Eng.28,8-18(2015).

[0406] 145.Yang J,Guo L.Biosynthesis ofβ-carotene in engineered E.coli usingthe MEP and MVA pathways.Microb.Cell Fact.13,160(2014).

[0407] 146.Zhao J,et al.Engineering central metabolic modules of Escherichiacoli for improvingβ-carotene production.Metab.Eng.17,42-50(2013).

[0408] 147.Li Y,et al.Metabolic engineering ofEscherichia coli using CRISPR–Cas9 meditated genome editing.Metab.Eng.31,13-21(2015).

[0409] 148.Luo Z,et al.Enhancing isoprenoid synthesis in Yarrowia lipolyticaby expressing the isopentenol utilization pathway and modulatingintracellular hydrophobicity.Metab.Eng.61,344-351(2020).

[0410] 149.hi B,et al.Systematic metabolic engineering of Saccharomycescerevisiae for lycopene overproduction.J.Agric.Food.Chem.67,11148-11157(2019).

[0411] 150.Ma T,et al.Lipid engineering combined with systematic metabolicengineering of Saccharomyces cerevisiae for high-yield production oflycopene.Metab.Eng.52,134-142(2019).

[0412] 151.Kang W,et al.Modular enzyme assembly for enhanced cascadebiocatalysis and metabolic flux.Nat.Commun.10,1-11(2019).

[0413] 152.Chen Y,Xiao W,Wang Y,Liu H,Li X,Yuan Y.Lycopene overproduction inSaccharomyces cerevisiae through combining pathway engineering with hostengineering.Microb.Cell Fact.15,113(2016).

[0414] 153.Xie W,Lv X,Ye L,Zhou P,Yu H.Construction of lycopene-overproducing Saccharomyces cerevisiae by combining directed evolution andmetabolic engineering.Metab.Eng.30,69-78(2015).

[0415] 154.Sun T,et al.Production of lycopene by metabolically-engineeredEscherichia coli.Biotechnol.Lett.36,1515-1522(2014).

Claims

1. A genetically modified yeast cell (modified cell), comprising: (i) a heterologous gene, wherein the heterologous gene encodes an enzyme having β-galactosidase (LacA) activity; (ii) one or more heterologous genes encoding one or more enzymes capable of converting lactate into pyruvate; (iii) one or more heterologous genes encoding one or more enzymes of the Leloir pathway; and (iv) one or more heterologous genes encoding one or more enzymes of the mevalonate pathway.

2. The modified cell of claim 1, wherein the modified cell is an oleaginous yeast cell.

3. The modified cell of claim 2, wherein the oleaginous cell is a Yarrowia lipolytica cell.

4. The modified cell according to any one of claims 1 to 3, wherein the one or more heterologous genes encoding one or more enzymes capable of converting lactate into pyruvate are selected from the group consisting of lactate transporter (JEN1) and lactate dehydrogenase (LDH).

5. The modified cell of any one of claims 1-4, wherein the one or more heterologous genes encoding one or more enzymes of the Leloir pathway are selected from the group consisting of GAL10M, GAL1, GAL7 and GAL10E.

6. The modified cell of any one of claims 1-5, wherein the one or more heterologous genes encoding one or more enzymes of the mevalonate pathway are selected from the group consisting of GGPPS, CarRP and CarB.

7. The modified cell according to claim 6, wherein the GGPPS is GGPPSxd derived from Xanthophyllomyces dendrorhous, GGPPSsa derived from Sulfolobus acidocaldarius, GGPPStc derived from Taxuscana densis, GGPPSpa derived from Pantoea agglomerans, or GGPPSyl derived from Yarrowia lipolytica.

8. The modified cell according to any one of claims 1 to 7, further comprising a heterologous gene encoding an enzyme having lycopene beta cyclase activity.

9. The modified cell according to claim 8, wherein the enzyme having lycopene β-cyclase activity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:

1.

10. The modified cell according to claim 9, wherein the enzyme having lycopene β cyclase activity comprises the amino acid sequence shown in any one of SEQ ID NOs: 2-4.

11. The modified cell according to claim 10, further comprising heterologous genes encoding tHMGR, ERG12, IDI and ERG20 of the mevalonate (MVA) pathway, and / or choline kinase (CK) and isopentenyl phosphate kinase (IPK).

12. The modified cell according to any one of claims 1 to 8, further comprising: (i) a heterologous gene encoding an enzyme having β-carotene ketolase (CrtW) activity; and (ii) A heterologous gene encoding an enzyme having β-carotene hydroxylase (CrtZ) activity.

13. The modified cell according to claim 12, wherein the enzyme having CrtW activity is fused with the enzyme having CrtZ activity (CrtW / CrtZ fusion enzyme).

14. The modified cell of claim 13, wherein the CrtW / CrtZ fusion enzyme comprises a localization signal.

15. The modified cell of claim 14, wherein the localization signal targets the CrtW / CrtZ fusion enzyme to the endoplasmic reticulum, peroxisome and / or lipid body.

16. The modified cell according to any one of claims 1 to 15, further comprising a heterologous gene encoding an enzyme having lycopene beta cyclase activity and / or a heterologous gene encoding an enzyme having lycopene epsilon cyclase activity.

17. The modified cell according to claim 16, wherein the enzyme having lycopene β-cyclase activity comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:

1.

18. The modified cell according to claim 16 or 17, further comprising a heterologous gene encoding an enzyme having carotenoid hydroxylase 1 (LUT1) activity and / or a heterologous gene encoding an enzyme having carotenoid hydroxylase 5 (LUT5) activity.

19. A genetically modified yeast cell (modified cell) comprising: (i) a first heterologous gene, wherein the first heterologous gene encodes an enzyme having β-carotene ketolase (CrtW) activity; and (ii) a second heterologous gene, wherein the second heterologous gene encodes an enzyme having β-carotene hydroxylase (CrtZ) activity; The modified cells produced beta-carotene.

20. The modified cell of claim 19, wherein the modified cell is an oleaginous yeast cell.

21. The modified cell of claim 20, wherein the oleaginous cell is a Yarrowia lipolytica cell.

22. The modified cell according to any one of claims 19-21, wherein an enzyme having CrtW activity is fused to an enzyme having CrtZ activity.

23. The modified cell of claim 22, wherein the CrtW / CrtZ fusion enzyme comprises a localization signal.

24. The modified cell of claim 23, wherein the localization signal targets the CrtW / CrtZ fusion enzyme to the endoplasmic reticulum, peroxisome and / or lipid body.

25. A method for converting a carbon source into lycopene and / or β-carotene, the method comprising: (i) contacting the modified cell according to any one of claims 1 to 11 with a carbon source; and (ii) incubating the modified cells with a carbon source for a sufficient period of time to convert the carbon source into lycopene and / or β-carotene.

26. The method of claim 25, wherein the carbon source is acid whey.

27. The method of claim 25 or 26, wherein the carbon source is converted into lycopene.

28. The method of claim 25 or 26, wherein the carbon source is converted to beta-carotene.

29. A method for converting a carbon source into astaxanthin, the method comprising: (i) contacting the modified cell according to any one of claims 12 to 15 or 19 to 24 with a carbon source; and (ii) incubating the modified cells with a carbon source for a period of time sufficient to convert the carbon source into astaxanthin.

30. The method of claim 29, wherein the carbon source is acid whey.

31. A method for converting a carbon source into α-carotene, the method comprising: (i) contacting the modified cell according to any one of claims 1 to 18 with a carbon source; and (ii) incubating the modified cells with a carbon source for a period of time sufficient to convert the carbon source into α-carotene.

32. The method of claim 31 , wherein the carbon source is acid whey.

33. A method for converting a carbon source into lutein, the method comprising: (i) contacting the modified cell according to any one of claims 1 to 18 with a carbon source; and (ii) incubating the modified cells with a carbon source for a sufficient period of time to convert the carbon source into lutein.

34. The method of claim 33, wherein the carbon source is acid whey.

35. An enzyme having lycopene β-cyclase activity, comprising the amino acid sequence shown in SEQ ID NO:

2.

36. An enzyme having lycopene β-cyclase activity, comprising the amino acid sequence shown in SEQ ID NO:

3.

37. An enzyme having lycopene β-cyclase activity, comprising the amino acid sequence shown in SEQ ID NO: 4.